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Summary: Association between BCG-induced immunity and risk of TB 
disease. Benjamin M. N. Kagina, 2nd June, 2010 
Tuberculosis is a pandemic disease. The incidence of the disease is 
particularly high in infants. The current vaccine against tuberculosis is 
therefore administered soon after birth. BCG protects against severe infant 
tuberculosis, but has variable and mostly poor protection against pulmonary 
disease. Consequently, development of more effective vaccines that protect 
against pulmonary disease is a priority. 
 
We tested the hypothesis that a lower frequency and profile of specific T cells 
induced by BCG vaccination at birth is associated with subsequent risk of 
developing tuberculosis. Whole blood from 10-weeks old infants, routinely 
vaccinated with BCG at birth, was incubated with BCG for 12 hours, followed 
by cryopreservation of white cells. Infants were followed for 2 years to 
identify those who developed culture-positive tuberculosis (cases), and those 
who did not, despite exposure to tuberculosis in the household (controls). 
Another group of randomly selected controls, never evaluated for TB, were 
also identified. Cells from cases and controls were thawed, and using flow 
cytometry, T cell-specific expression of IFN-γ, TNF-α, IL-2, and IL-17 was 
measured. The BCG-specific T cell cytokine frequencies and profiles did not 
associate with risk of developing tuberculosis. We concluded that critical 
components of immunity against tuberculosis, such as IFN-γ  production by 
CD4 T cells, may not translate to correlates of risk of tuberculosis. 
 
We also tested the hypothesis that delaying BCG vaccination from birth to 
10-weeks of age results in induction of more optimal specific T cell immunity. 
The rationale is that we may be able to use BCG more optimally by later 
administration, given the relative “immaturity” of the newborn’s immune 
system. BCG was either administered at birth or at 10 weeks of age. Ten 
weeks after vaccination, and at 1 year of age, vaccine-specific T cell 
expression of IFN-γ, TNF-α and IL-2, were measured with the same whole 
blood assay. The responding specific T cells were phenotyped for memory 











higher frequencies of BCG-specific CD4 T cells, particularly polyfunctional T 
cells co-expressing IFN-γ, TNF-α and IL-2, and most strikingly at 1 year of 
age. We concluded that BCG might be used more optimally, if given later 
than immediately after birth. 
 
The findings in this thesis are contributing significantly to the field of 
tuberculosis vaccinology. For example, new approaches to delineating host 
correlates of risk of tuberculosis are needed, and the effect of age of giving 
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(i) To assess whether long-term cryopreservation would allow reliable 
measurement of mycobacteria-specific T cell response (Chapter 2) 
(ii)  To optimize a polychromatic flow cytometry panel for the 
measurement of BCG-specific T cells in infants (Chapter 3) 
(iii)  To evaluate the association between the frequency and cytokine 
expression profiles of antigen-specific T cells with the risk of childhood TB 
disease, following BCG vaccination at birth (Chapter 4) 
(iv)  To assess the effect of delaying BCG from birth to 10 weeks of age on 











Chapter 1: General introduction 
 
1.1 What is tuberculosis? 
Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (M.tb). 
TB disease mainly occurs in the lungs although it may disseminate to other 
organs (1). TB diseased persons cough, allowing airborne transmission to 
others, who inhale the pathogen. Infants and children younger than four 
years are at greater risk of developing TB disease after primary M.tb 
infection, compared with older children, adolescents and young adults (2, 3). 
Therefore, this thesis has focused on TB immunology studies in infants. 
 
1.2 Epidemiology of tuberculosis  
In 2008, the World Health Organization (WHO) estimated a TB incidence of 
139 cases per 100,000 populations, globally (4). Africa and Asia had the 
most number of TB cases globally (4). Based on TB incident rates, 22 high 
burden countries have been identified by WHO, and South Africa is ranked 
fifth on the list of these countries (4). In South Africa, the Worcester region of 
the Western Cape has a TB incidence in excess of 1,000/100,000/year 
among children <2 years of age (5). 
 
The South African Tuberculosis Vaccine Initiative (SATVI) established a 
vaccine evaluation site in the Worcester region in 2000. Our aim was to study 
new TB vaccines, and address clinical, epidemiological and immunological 
questions that are critical for TB vaccine development. Some of the studies 
reported in this thesis were performed on infant participants recruited from 
the site. 
 
1.3 Natural history of tuberculosis 
Tuberculosis diseased persons expel M.tb into the air when they cough or 
sneeze. The bacterium is contained in the aerosol droplets. Healthy 
individuals who inhale M.tb contained in the aerosol microdroplets may: (i) 
resist infection, (ii) become infected and develop TB disease (primary TB), 











latently infected, and later progress to TB disease (secondary or reactivation 
TB) (6). In absence of human immunodeficiency virus (HIV) infection or any 
other immunosuppressive condition, it is estimated that 5% of latently M.tb 
infected people progress to develop active TB within five years and another 
5% reactivate to active TB during their lifetime (7). If no preventative 
measures are implemented, infants below one year of age have the highest 
risk of progressing to TB disease following primary M.tb exposure; up to 30% 
develop pulmonary or disseminated TB within one year (2). Figure 1 
illustrates the possible outcomes of a host following M.tb exposure. 
 
 
Figure 1: The possible outcomes of host exposure to M.tb: (i) Some individuals successfully 
clear the infection, (ii) others contain the infection, (iii) while the remaining individuals 
develop primary TB disease. Differences in innate and adaptive immunity may account for 
these potential outcomes. Five-percent of the latently infected individuals progress to 
secondary TB disease within five years while another five-percentage progress to TB 
disease during their lifetime. In the presence of immunosuppressive conditions, the risk of 
progressing to TB disease is increased. The figure is adapted from Bhatt et al.(8). 
 
 
1.3.1 Risk modifiers to tuberculosis natural history 
Several risk modifiers may play a role in the natural history of TB within a 
host. These risk modifiers include: 
(a) Host genetic factors. Some genetic determinants have been linked 
with susceptibility to M.tb infection and subsequent progression to TB 











al. found that a single nucleotide polymorphism (SNP) of CD209 at 
two alleles; -871G and -336A was associated with decreased TB 
susceptibility (9). Also, among Chinese patients with coal worker's 
pneumoconiosis, presence of a SNP in the tumor necrosis factor 
(TNF-α)-308A allele was reported to be associated with an elevated 
risk for pulmonary TB (10). Among others, susceptibility to TB may 
also be influenced by genetic variants of the major histocompatibility 
complex (MHC), the macrophage protein solute carrier family 11 
member a1 gene (SLC11A1; also known as natural resistance 
associated macrophage protein, NRAMP), receptors to vitamin D, 
molecules in the interferon gamma (IFN-γ)/interleukin twelve (IL-12) 
pathway, as well as molecules in nitric oxide synthase pathways (11-
14). 
(b) Age. The neonate’s immune system is less “mature”, compared with 
that of adults (15-18). Consequently, n wborns are more susceptible 
to multiple infections, including M.tb. Independent of factors such 
HIV/AIDS, environment, genetics or social-economic status, infants 
and children are at higher risk of developing TB disease after M.tb 
infection, as mentioned above (2). In South Africa, TB disease case 
notification rates was shown to be 3.5 times higher in 0-5 year old 
children than in adults (19). Thus, infants should be a target 
population for vaccination with an effective TB vaccine. Assessment of 
correlates of risk of TB disease in infants may hold clues to critical 
aspects of immunity that predispose infants to greater risk of 
development of TB. 
(c) Immune suppressive conditions. Persons with immune suppressive 
conditions such as diabetes mellitus and HIV/AIDS are more 
vulnerable to established M.tb infection and subsequent TB disease 
development (20, 21). One possible explanation to vulnerability in 
M.tb/HIV co-infected persons is the HIV-associated apoptosis of CD4 
T cells (22), a subset of immune cells that has been shown to be 
necessary for protective immunity against TB (23). A study by 











infected infants were 24 times more likely to develop TB than HIV-
uninfected infants (20). 
(d) Socio-economic factors. A strong association was reported between 
homelessness and the incidence of TB in a community living in the 
northern region of Poland (24). A positive relationship between 
crowded environments (25), poverty (26) with TB incidence has been 
reported. 
 
1.4 Interventions against tuberculosis 
In response to the morbidity and mortality associated with TB, the WHO 
together with various stakeholders has suggested multi-pronged 
interventions: 
(a) TB diagnosis. Sensitive and rapid diagnosis of TB is critical for control 
of TB pandemic. Clinical, radiological as well as epidemiological 
scoring systems, sputum microscopy, detection of M.tb cellular 
components by molecular methods, and detection of host-specific 
immune response to M.tb are some of the main laboratory methods of 
diagnosing TB (27-30). Tuberculin skin test (TST) and IFN-γ release 
assays (IGRAs) detect the host immune response to M.tb antigens, 
and are widely used in the diagnosis of latent TB. The TST assesses 
the host delayed hypersensitivity reaction, characterized by 
inflammation of the dermis at the site of purified protein derivative 
(PPD) i jection. M.tb PPD consists primarily of membrane proteins 
derived from this pathogen, but these proteins are very similar across 
mycobacterial species (31). Consequently, the TST response may 
also be positive in individuals previously vaccinated with BCG as well 
as individuals exposed to environmental mycobacteria (32). On the 
other hand, IGRAs measure the host IFN-γ responses following 
incubation of whole blood with M.tb-specific antigens of the region of 
difference (RD-1) that includes ESAT6, CFP10 and TB7.7, by 
enzyme-linked immunosorbent assay (Elisa) or enzyme-linked 
immunosorbent spot (Elispot) (33). Therefore, IGRAs are more 











for TB infection than TST, at least in low-prevalence countries (34, 
35). In children less than five years old, the reliability of IGRAS has 
not yet been determined (36), especially not in the presence of 
malnutrition and immune deficiency. Malnutrition and HIV associated 
immune deficiency are most prevalent in TB endemic countries (37) 
where timely diagnosis is much needed. The gold standard for 
diagnosing TB disease is bacteriological confirmation in sputum 
samples (29). The sensitivity of sputum microscopy and culture to 
diagnose TB disease in children is compounded by the pauci-bacillary 
nature of childhood TB and the difficulty of obtaining these samples for 
culture (27). Therefore, clinical and radiological features are often 
used to make the diagnosis in this population; many of these markers 
are non-specific. 
(b) TB treatment. The WHO target for successful treatment is a cure rate 
of 85% of the 70% TB cases detected (38). Optimal implementation of 
the directly observed treatment strategy (DOTS), introduced by WHO 
in the mid 1990s (39), is key to achieving treatment targets. The 
principle of treating children and adults for TB is similar (40). Drugs 
used in the treatment of TB are classified as first-line, second-line or 
third-line mainly, based on efficacy and drug sensitivity (41). 
Treatment can either be to prevent latent TB from progressing to 
disease, or to treat TB disease itself (42). Treatment of latent TB in 
children involves first line drugs like isoniazid for 6 months or 
rifampicin and isoniazid for 3 months (43). This treatment is well 
tolerated (44) and can achieve 60-80% efficacy in prevention of TB 
disease (45). To achieve microbiological cure of drug susceptible M.tb 
in patients with TB disease, multiple first-line TB drugs must be taken 
daily for at least 6 months (46). Compounding this protracted TB 
treatment is the rapid resolution of clinical symptoms prior to the 
required period of TB chemotherapy (47). Consequently, some 
patients do not strictly adhere to the anti-TB drug treatment schedule, 
which may lead to outgrowth of resistant organisms (48). TB patients 
with multiple drug resistance (MDR) M.tb strains are treated with the 











capreomycin (41). These second-line drugs are more toxic and 
expensive than first-line drugs (41). Third-line drugs such as rifabutin, 
clarithromycin and linezolid are used for treating patients with 
extensively drug resistant (XDR) M.tb strains, and are even more toxic 
and expensive than second-line drugs (41). 
(c) TB vaccines. BCG is the only vaccine currently available for use to 
prevent TB. The vaccine is effective against severe forms of TB in 
children (49). However, BCG is not very effective at preventing 
pulmonary TB, the most prevalent form of the disease (50). There is a 
general consensus among health experts that an effective vaccine 
against TB would be the most pragmatic approach in addressing the 
pandemic. Abu-Raddad et al. used a mathematical model to show that 
if all the novel TB interventions (drugs, vaccines, diagnostics) currently 
in development were successful, the greatest reduction in TB 
incidence would be achieved through effective neonatal vaccination 
(51). Therefore, development of more effective TB vaccines against 
the pandemic is a priority in TB intervention list. New TB vaccines may 
either be preventive or therapeutic (52). Among preventive vaccines, 
prime vaccines are intended for use in newborns and infants prior to 
M.tb or environmental NTM exposure. BCG, modified BCG and 
attenuated M.tb are examples of this type of vaccine (52). Knowledge 
of variables such as age of vaccination, dose as well as the type of 
immunity elicited by the prime vaccines is vital for their optimal use. 
Chapter five studies in this thesis evaluated the effect of delaying BCG 
to 10 weeks of age on the BCG-induced immunity. In the absence of 
known immune correlates of protection against TB, the optimal age to 
give the second type of preventive vaccine, a boost vaccine, is not 
known. Establishing the optimal age to give the boost vaccine is still 
an active area of research. Nevertheless, epidemiological data 
indicate the administration of booster TB vaccines may be ideal during 
the first two years of life and early in adolescence; TB incidence has 
been shown to peak in infancy and during adolescence (2, 19). Boost 
vaccines classically consist of specific mycobacterial antigens 











adjuvants. Novel therapeutic TB vaccines would be given to 
individuals with active TB. These vaccines would complement the 
antibiotic treatment, thereby shortening the duration of anti-TB 
chemotherapy. Proposed candidate therapeutic TB vaccines include 
inactivated mycobacteria and DNA subunit vaccine encoding for 
mycobacterial heat-shock proteins (52). 
(d) Public health interventions. TB diseased persons who are not taking 
anti-TB drugs spread the disease. Rapid identification and treatment 
of these infectious persons within a population is therefore central in 
the control of the disease. Upon initiation of TB chemotherapy to 
control infectious cases, DOTS is integral in ensuring patients adhere 
to the treatment schedule. In most countries, national TB programs 
have been established to coordinate TB control efforts. The success 
of national TB programs to achieve timely TB case detection, 
treatment as well as adherence to the treatment is dependent on 
optimal national health system (53). Bottlenecks cited with suboptimal 
health systems include lack of adequate health workforce, financing, 
drug supply, information systems and governance (53). Reforms 
geared at addressing these bottlenecks in health systems have been 
shown to significantly improve national TB control programs, and 
subsequently reduce the disease burden (53). For example, Wang et 
al. reported significant improvements in TB control in China, largely 
due to reforms of the national health care system (54). In South Africa, 
health sector reforms that allowed for the creation of district health 
system were reported to have substantial success in the management 
of TB (55). 
 
1.5 Success of Mycobacterium tuberculosis in the face of the current 
vaccine 
Despite decades of global and national TB control programs as well as BCG 
still being one of the most widely used vaccine within the expanded program 
of immunization (EPI) (56), (in 2008, BCG had over 80% global vaccination 











M.tb to cause human morbidity and mortality can partly be attributed to 
several survival mechanisms the bacilli has adopted to survive in the hostile 
host environment. Many M.tb survival strategies have been described, 
including the DNA repair mechanism that involves DnaE2 enzyme, restoring 
damage to the bacterial DNA caused by the host immune defenses (59). 
Another survival mechanism of M.tb is the ability to arrest phagosome 
maturation through mechanism of pH homeostasis within the macrophages 
(60). This allows the intracellular M.tb to undergo uncontrolled growth. M.tb 
has also been shown to express nicotinamide adenine dinucleotide (NADH)-
dependent peroxidase and peroxynitrite reductase that detoxify reactive 
oxygen species (ROS) and reactive nitrogen species (RNS), produced by the 
host antigen presenting cells (APCs) (61). This renders M.tb resistant to the 
host antimicrobial components. Development of new vaccines would 
therefore not only require identification of correlates of protection, for 
example, but also intensive basic science research into mechanisms to 
circumvent bacterial evasion of the host response. Multiple drugs and 
vaccine candidates that specifically address this issue are under 
development (62-64). 
 
1.6 Host immunity to Mycobacterium tuberculosis  
1.6.1 Innate immune response to Mycobacterium tuberculosis  
Interaction of the inhaled M.tb and the host immune cells begins in the 
alveoli, tiny sacs in the lungs specialized in gaseous exchange. In the alveoli, 
APCs which include alveolar macrophages, dendritic cells (DCs) and 
polymorphonuclear neutrophils (PMNs) patrolling the distal airways may 
directly phagocytose the bacilli (65). The uptake of the bacilli by a host APCs 
is via phagocytic and recognition receptors (66-68). These receptors among 
many others include mannose-containing glycoconjugates, Fc gamma 
receptor, complement receptor, C-type lectins such as dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC SIGN) and 
dectin-1, toll like receptors (TLR), CD43 and CD14 (69-72). Differential 
receptor interaction will result in distinct functional consequences, such as 











cytokine or chemokine production or MHC expression (73, 74). It is thought 
that the initial interaction between M.tb and the host APCs determines the 
subsequent immune response. This is partly because of differential induction 
and constitutive expression of recognition and phagocytic receptors on 
various APCs (75).  
 
The PMNs are short-lived and undergo apoptosis soon after phagocytosis of 
the M.tb (76). In a mouse model of virulent M.tb challenge, depletion of 
PMNs resulted in a decreased recruitment of specific Th1 cells (77). This 
suggests that these cells (PMNs) may also play a critical role by producing 
chemokines that attract other mycobacteria-specific cells to the site of 
infection. In vitro experiments have shown that human PMNs can inhibit 
growth of both BCG and M.tb, via production of antimicrobial peptides such 
as cathelicidin LL-37 and lipocalin 2 (78). Some alveolar macrophages may 
also undergo apoptosis following increased burden of the M.tb in the 
phagosome (79, 80). The apoptotic APCs are taken up by secondary 
alveolar macrophages and DCs. Once phacocytosed by the DCs or 
secondary alveolar macrophage, the bacilli are again contained within 
phagosomes (81, 82). Knowledge on the killing mechanisms of the 
intracellular M.tb by the host APCs in humans remains incomplete. However, 
in animal models, it has been shown that, the bacilli in the phagosome may 
be killed by antimicrobial components that include lysosomal enzymes, ROS, 
siderocalin and RNS (83-85). Autophagy provides an additional route for the 
elimination of the intracellular M.tb by the host APCs (86, 87). In this process 
(autophagy), intracellular M.tb escaping into the cell cytoplasm may be 
sequestered together with other cellular cytoplasmic entities, and then 
targeted for degradation by fusion with lysozomes (88).  
 
Natural killer (NK) cells are also thought to be important in mediating 
immunity against M.tb infection. Experimental data show that NK cells can 
recognize and lyse M.tb infected monocytes and macrophages through 
production of cytotoxic molecules (89). Furthermore, NK cells produce 
cytokines, mainly IFN-γ, that can shape the adaptive response to M.tb. (90). 











the APCs to establish an infection. If not killed, the intracellular M.tb may 
then undergo a growth phase within the APCs to establish an infection. 
Inability by the host immune response to control the M.tb replication results 
to development of clinical TB disease whereas the ability by the host to 
control the M.tb replication results to sub clinical TB. The innate system 
alone may not be adequate to control the infection – help from T cells, which 
activate the phagocytes, may be necessary (see below). Essentially, innate 
immune cells constitute the first line of defense by the host immune system 
against M.tb. 
 
1.6.2 T cell immune response to Mycobacterium tuberculosis  
Dendritic cells infected with M.tb migrate from the site of infection to the 
draining lymph nodes and present the M.tb peptides to cognate T cells to 
initiate a second line of host defense, which is cell mediated immunity (91, 
92). These T cells respond by producing cytokines such as IFN-γ that 
activates the APCs to enhance control of the intracellular M.tb (93). 
Additionally, the activated T cells produce cytotoxic molecules such as 
perforin, which mediate lysis of M.tb infected cells, or granulysin, which may 
kill mycobacteria directly (94, 95). Thus, a positive loop exists whereby the 
activated APCs produce cytokines such as IL-12 that drive differentiation of 
Th1 cells while T cells produce IFN-γ that activate the APCs. It is presumed 
that optimal innate and optimal adaptive immunity act synergistically to limit 
the bacilli growth by formation of granulomas in the lungs. Granulomas 
comprising macrophages, epithelioid cells, multinucleated giant cells, and 
lymphocytes, are the pathologic hallmark of TB, and are thought to contain 
M.tb infection (96, 97). Conversely, suboptimal innate and adaptive immunity 
may lead to poor granuloma formation, resulting in spread of M.tb infection 
and subsequent development of TB disease. The exact immune factors and 
mechanisms that lead to the successful or unsuccessful local immune 
response to M.tb infection are poorly understood. Additionally, immune 
correlates of protection against TB are not known. The identification of the 
correlates and biomarkers of protection against TB may accelerate the 











to design a vaccine with properties that can induce the desired immunity. In 
view of guiding novel TB vaccine development and testing, our chapter four 
studies investigated the correlates of risk against TB disease in newborns 
following BCG vaccination at birth. 
 
1.6.3 Summary of immunity to Mycobacterium tuberculosis 
 
Figure 2: Immune response and regulation during M.tb infection. Molecules shown on 
the left side with a “+” sign are thought to mediate immunity during M.tb infection while 
molecules shown on the right side with a “-“ sign are thought to regulate the response. 
Optimal outcome is thought to result from a balance between the two processes.  
 
 
1.7 Immune correlates of protection against TB 
Immune correlates of protection are defined as measurable host responses 
to a vaccine or infectious agent indicating resistance to developing disease 
(98). Vaccination-induced correlates of protection may be identified in a 
randomised controlled trial of an effective vaccine; in the interim, we are 
studying correlates of risk (CoR) of TB disease, with the hope that these will 












Investigation of immune CoR of TB disease is only feasible in well-designed 
cohort studies. Furthermore, it is becoming clear that following M.tb infection 
to a host, a wide spectrum of host responses may underlie the clinical state 
of “latency” (100). This spectrum needs to be taken into account in studies of 
CoR. Studies aimed at investigating immune CoR of TB disease begin with 
optimal selection of study population, definition of TB cases, and delineation 
of optimal follow up time. Our immune CoR studies involved large number of 
infants (over 5,000), which is essential for these studies, and utilized qualified 
diagnostic algorithms to define TB cases, which is also critical (101). Only 
then can investigators decide which host parameters to assess, and second, 
how to measure these potential markers. From our current understanding of 
M.tb immunobiology, potential CoR of TB disease may be classified into 2 
groups: factors associated with too much inflammation, and factors 
associated with excessive anti-inflammatory responses and excessive 
regulation of potentially protective effector responses. Pro-inflammatory 
factors may be associated with innate cells, including production of IL-1, IL-6, 
IL-12, or associated with T cells, such as effector Th1 or Th17 responses, or 
cytotoxic activity (102); excessive activity of these responses, which may all 
be important for protection, could be deleterious. Therefore, anti-
inflammatory factors produced by innate cells, such as IL-10, and even Th2 
responses or Treg activity may be important. Our focus in this thesis was on 
Th1 and Th17 responses, hypothesizing that optimal responses by these 
cells, and not excessive or too little, may be associated with protection 
against TB disease. It should be pointed out that we recognise the potential 
limitations of this reductionist approach. Therefore, many modern CoR 
studies have employed unbiased approaches, such as metabolomics, 
transcriptomics and proteomics, in an attempt to define these host markers 
that associated with outcome (103). 
 
The importance of identifying immune correlates of protection against TB 
cannot be overemphasized. First, reliable correlates of protection would 
guide rational design of novel TB vaccines. Second, the correlates of 
protection would allow a more focused and standardized immunogenicity 











effective TB vaccines are available and licensed for human use, identification 
of populations at the highest risk of developing TB disease is feasible, 
allowing for timely, targeted intervention and subsequent reduction of TB 
incidence rates. 
 
1.8 Vaccine induced immunity against Mycobacterium tuberculosis 
1.8.1 Principles of vaccine induced immune protection 
Broadly, immunity can be defined as the ability of the body to protect itself 
against non-self agents such as pathogens. Vaccination aims to invoke 
immunity that confers long-term protection against a pathogen. To achieve 
this, vaccines must contain some or all antigens of the target infectious agent 
that are recognized by the immune system, for an effective host response. 
More importantly, the vaccine must be safe. There are three main categories 
of vaccines used in humans: inactivated pathogens, live attenuated 
pathogens and subunit vaccines. Vaccine-induced immunity may be B or T 
cell-mediated, although a combination of the two arms is often required after 
vaccination (104). T cell immunity is thought to be necessary in conferring 
protection against M.tb. Therefore, majority of new TB vaccines are designed 
to induce this type of immunity and is the most commonly assessed immune 
response in clinical trials testing for novel TB vaccines (105, 106). 
 
The vaccine-induced T cell immune response is initiated when antigens 
contained in the vaccine are taken up by APCs (107). In the peripheral 
tissues, uptake of the vaccine antigens by immature DCs initiates activation 
and maturational changes, which are aided by local inflammatory mediators 
such as cytokines, chemokines and prostaglandins (108). DC maturation 
involves many morphological and cytoskeletal changes such as upregulation 
of surface receptors, e.g. chemokine receptors (CCR7 and CXCR4) and 
costimulatory molecules (CD80 and CD86) (108). The local 
microenvironment also provides signals required for the DC migration to the 
secondary lymphoid organs (108, 109). Activated, antigen loaded and 
matured DCs process the antigens and migrate to the draining lymph nodes 











antigen-specific naive T cells (107). In the lymph node, antigen-specific naive 
T cells become activated and differentiate in to effector T cells (107). The 
effector CD4 T cells, and other cells from the microenviromnent, provide 
additional stimuli allowing DCs to polarise into APC providing naive CD4 T 
cells with signals to differentiate into distinct types of effector T-helper cells, 
e.g., Th1, Th2, Th9, Th17, and inducible regulatory T cells (iTreg) (109). 
Therefore, DCs play a critical role in orchestrating vaccine-induced immunity 
to the targeted organisms. 
 
Antigen-specific effector T cells are short lived (107). When the vaccine is 
cleared, a small population of clonally expanded antigen-specific 
lymphocytes is maintained as a memory pool. The memory pool rapidly 
mounts a protective response upon later, secondary encounter with vaccine 
directed pathogen (110, 111). Figure 3 illustrates the possible mechanisms 




Figure 3: Antigen Presenting Cells (APCs), represented by dendritic cells (DCs) take up the 
vaccine or pathogen. The DCs become activated and process the complex antigens into 
peptides. The B cells may also take up antigen and present to T cells (stage 1). Activated 
DCs present the peptides to cognate CD4 and CD8 T cells (stage 2). In the presence of co-
stimulation and cytokines, T cells become activated and proliferate (stage 3). Proliferating T 
and B cells differentiate into effector cells (stage 4) that can carry out effector functions. 
Activated CD4 T cells can also provide help to B cells, inducing the production of high-affinity 
class switched antibody (stage 5). After a successful immune response, effector cells 
apoptose, leaving a small pool of long-lived memory B and T cells, which is the ultimate goal 












The necessary vaccine-induced effector/memory immunity against M.tb is 
thought to involve CD4 and CD8 T cells that make type 1 cytokines and have 
cytotoxic activity (Tc). Pro-inflammatory IL-17-producing T cells (Th17) may 
also play a role (112-114). Although the role of IL-17-producing T cells in 
mediating immunity against M.tb infection is unclear in humans, experimental 
data support the importance of these cells in TB immunity. For example, 
Wozniak et al. reported that mice deficient of the IL-12/IFN-γ axis developed 
a robust Th17 T-cell response after BCG immunization, and this response 
was associated with a significant reduction in the bacterial load following 
infection with M.tb (115). Other investigators have reported that in vivo 
transfer of mycobacteria-specific IL-17-secreting CD4 T cells to susceptible 
mice [IL-12p40(-/-) or RAG(-/-)] resulted in a significant reduction in the 
bacterial load following M.tb challenge (116). It is likely that optimal vaccine-
induced immune responses need to be regulated to avoid immune pathology. 
Mechanisms that regulate Th1 immunity may include type 2 cytokines (Th2) 
and regulatory CD4 T cell (Treg) activity (117-120). Among effector T cells, 
multiple negative regulatory pathways control activation. These involve 
molecules such as programmed death-1 (PD-1), cytotoxic T-lymphocyte 
antigen 4 (CTLA-4), T cell immunoglobulin mucin-3 (TIM-3), B and T 
lymphocyte attenuator (BTLA), CD244 and lymphocyte-activation gene 3 
(LAG-3), among many others (121, 122). It is likely that a balance between 
the vaccine-induced immune response and the immune regulatory factors is 
critical. For example, excessive anti-inflammatory and regulatory factors 
involving Th2 and Tregs, respectively, may attenuate the protective response 
(123). This may result in host suboptimal response against M.tb infection. It 
is thought that an interplay and counter regulation of the pro-inflammatory, 
anti-inflammatory, and regulatory mechanisms influence the outcome of M.tb 
infection within the host. Consequently, evaluation of antigen-specific pro-
inflammatory, anti-inflammatory, and regulatory factors could provide key 
insights to candidate immune correlates of protection against TB. Although it 
may be therefore important to measure all these aspects of immunity, work in 













1.8.2 Bacille Calmette-Guérin vaccine in tuberculosis control 
Bacille Calmette-Guérin (BCG) is a live attenuated strain of M.bovis. The 
vaccine was first introduced in humans in 1921 and adopted by the WHO in 
1948 (124). When administered at birth, BCG affords about 80% protection 
against miliary and meningeal TB in children (125). In addition, non-specific 
benefits of neonatal BCG vaccination have been reported (126). These 
include reduced childhood mortality in infants from low socio-economic 
environment, not related to protection against TB, protection against other 
environmental mycobacterial diseases and enhanced immunogenicity and 
possibly protection afforded by other vaccines given within the EPI (127). 
The vaccine has good safety record in healthy newborns. BCG is widely 
used: an estimated 100 million children receive BCG every year (124). 
However, despite the widespread use of BCG, the gl bal TB burden remains 
very high: about 1.7 million TB associated deaths occurs annually and one-
third of the world’s population is asymptomatically infected with M.tb (128). 
 
Epidemiological data indicates that BCG has variable efficacy against 
pulmonary TB (50). This efficacy appears to vary in different geographical 
regions (50), suggesting influence of the environment; genetic factors may 
also be important. Several hypotheses on immunological explanation to the 
variability in BCG efficacy have been tested. For example, Peiying et al. 
reported that splenocytes from mice that are presensitised with NTM followed 
by intranasal BCG challenge exerted a stronger cytotoxic activity against 
autologous BCG-infected macrophages than mice without NTM 
presensitisation (129). This suggests that pre-existing host NTM induced 
immunity may mount an immune response against BCG, resulting to reduced 
vaccine-induced immunity. 
 
BCG vaccination induces a predominant Th1 response (130, 131). This type 
of immune response is thought to be important for protection against TB. The 
administration of BCG vaccine to the host is aimed at mimicking the 
response to natural and potentially harmful M.tb infection. Therefore, the 











similar to that following M.tb infection. However, BCG is routinely given 
intradermally, implying the uptake of the vaccine antigens by the host APCs 
in the intradermal tissue and not by alveolar macrophage, as is the case of 
M.tb. In clinical settings, it is not known whether intranasal or even 
pulmonary delivery of BCG would elicit a more effective immune response 
and better protection against M.tb. The immunogenicity assays performed 
during novel TB vaccine clinical trials commonly assess the Th1 response, 
with presumption that this response may associate with the vaccine efficacy. 
However, it is not known whether the mycobacteria-induced Th1 immune 
response translates to protection against development of TB. In this thesis, 
we assessed whether the age at which BCG is administered may influence 
BCG-induced immunity. We also assessed if the BCG-induced Th1 immunity 
would correlate with the risk of developing TB. 
 
1.8.2.1 Factors that may influence BCG-induced immunity 
Factors thought to influence BCG immunogenicity include (i) age at which 
BCG vaccination is administered, (ii) vaccination route, (iii) pre-exposure to 
NTM, (iv) BCG strain and (v) host genetic factors. 
a) Age at which BCG vaccination administered: Most TB endemic 
countries, including South Africa have adopted at birth or soon after 
birth BCG vaccination schedule. This is in line with the WHO TB 
control vaccination policy (132). In high TB prevalent areas, the risk of 
early M.tb exposure to infants is high. Also, majority of births occur in 
health facilities, ideal settings to give BCG and other EPI vaccines. 
This vaccination schedule results to higher BCG vaccination coverage 
than if delayed to a later stage. However, the neonate’s immune 
system is adapted towards an in utero environment, implying a bias 
towards a Th2 response (133), and an increased frequency of Tregs 
(134). Furthermore, some studies have reported reduced functional 
capacity of neonatal APCs relative to those of adults (135). These 
characteristics may result in a suboptimal immune response to BCG 
when administered at birth. A study by Hussey et al. reported no 











delayed for 10 weeks as assessed by soluble cytokine levels (136). 
However, BCG-induced T cell immunity in infants is complex (130), 
and cytokine co-expression profiles were not evaluated in this study. 
We therefore proposed to comprehensively assess the effect of age at 
which the BCG vaccine was given on the vaccine-induced T cell 
immunity in infants.  
b) Vaccination route: In clinical settings, BCG is administered either 
percutaneously or intradermally. Factors considered in the choice of 
administration route may include ease of delivery, costs, consistency 
of dose delivery, adverse events or immunogenicity. The APCs are 
the first immune cells to take up BCG in the host. Different types of 
APCs are compartmentalized within different tissue types of the host 
(137). Compartmentalized APCs have been shown to have distinct 
functional capacity (138). It is likely that different BCG delivery routes 
activate distinct types of APCs. This may result in differential induction 
of BCG-specific immune responses. Furthermore, it has been shown 
that intradermal or intramuscular vaccine routes may result in varying 
immunogenicity against Hepatitis B (139), rabies (140), or influenza 
viruses (141). Additionally, in orthopoxvirus vaccinia virus challenge 
mouse model, skin scarification generated superior T cell-mediated 
immune responses and better protection, compared with intradermal, 
intramascular or intraperitoneal vaccinia virus vaccination (142). A 
study in our laboratory showed that infants vaccinated via these two 
classical BCG vaccination routes were at similar risk of developing TB 
(101). Therefore we did not focus our studies to assess for the effects 
of vaccination route on BCG-induced immunity. 
c) Pre-exposure to environmental non-tuberculous mycobacteria (NTM): 
Several different strains of NTM have been described (143). Most 
NTM species have >95% genetic similarity with BCG (144), and are 
mainly found in soil and open waters (145). It is likely that BCG and 
most NTM possess similar antigens that induce cross-reactive 
immune responses. Furthermore, in a mouse model, pre-sensitization 
with NTM prior to BCG vaccination was shown to reduce the vaccine 











Such preclinical findings on the influence of NTM exposure prior to 
BCG vaccination have raised concerns related to vaccine 
immunogenicity in clinical settings with high prevalence of 
environmental NTM. Coincidentally, a much more reduced BCG 
efficacy level is reported in countries within the tropics (50, 147). It is 
known that NTM are highly prevalent in these settings. Weir et al. 
reported that NTM exposure prior to BCG vaccination in Malawian 
school children did not reduce BCG immunogenicity when assessed 
by an in vitro 6-day whole blood IFN-γ response to mycobacterial 
antigens (147). However, although hypotheses exist, there is still no 
clear clinical evidence in clinical settings that pre-sensitization of the 
immune system by NTM, prior to BCG, might reduce or enhance the 
vaccine immunogenicity. In countries like South Africa where BCG is 
given at birth before potential exposure to NTM, the vaccine-induced 
immune responses may be independent of NTM pre-sensitization. In 
one of our clinical studies where BCG was administered at birth or at 
10-weeks of age, collaborators from Stellenbosch University are 
evaluating whether NTM exposure may have any influence to BCG-
induced immunity. 
d) BCG strains: Changes in culture media and colony transfer schedules 
during the BCG manufacturing process are some of the key changes 
introduced in order to speed up production of the vaccine (148, 149). It 
is thought that some of these changes in processing of the vaccine 
may have resulted in different BCG substrains (150). Currently, over 
49 BCG vaccine strains are known to exist, of which 4 are most widely 
administered worldwide, namely Danish, Japan, Glaxo, and Pasteur 
(151). Genomic analysis has identified a number of polymorphisms in 
different BCG strains (150). Some of these polymorphisms are located 
in genes encoding virulence factors and possibly inducing relevant 
immune responses (150). Knowledge on whether these 
polymorphisms impact on BCG-induced immunity is incomplete. In a 
guinea pig model with M.tb challenge after BCG vaccination, Horwitz 
et al. reported no difference in the protective efficacy of six different 











which BCG strain is more efficacious or induces a more optimal 
immune response. As such, the choice of which BCG strain to use in 
different countries may largely depend on factors unrelated to 
immunogenicity. In July 2000, the South African Department of Health 
recommended the change of BCG vaccine from the routinely used 
Japan to Danish strain (153). For the immune CoR studies reported in 
this thesis, BCG strain (Tokyo 172) was administered randomly to the 
participants either via percutaneous or intradermal routes (101).  
e) Host genetic factors: Several studies have investigated the role of host 
genetics in the development of TB. For example, Greenwood et al. 
reported an association between intragenic variants of natural 
resistance–associated macrophage protein 1 (NRAMP1) gene and 
susceptibility to mycobacterial diseases in a community of Aboriginal 
Canadians (154). Susceptibility to TB has been linked to genetic 
polymorphisms on TLR expressed on macrophages and other 
leukocytes, and involved in M.tb and BCG recognition by the host 
APC (155). Our laboratory is currently conducting studies to 
investigate the role mediated by mycobacterial recognition genes on 
BCG immunogenicity and TB disease outcome. 
f) Host immune deficiency: BCG is a live vaccine that replicates in the 
host and can cause disease (BCGosis) in an immunocompromised 
host. In South Africa, among HIV-infected infants, an estimated 110-
417 cases of BCGosis are reported per 100,000 BCG vaccinations 
(156). Furthermore, studies in our laboratory have shown that BCG-
induced immunity is severely compromised in HIV-infected infants 
(157, 158). Such findings have necessitated a policy review by the 
WHO Global Advisory Committee on Vaccine Safety, who has stated 
that BCG should not be given to infants known to be HIV-infected 
(159). Since it is not feasible to accurately determine presence of HIV 
infection in newborns due to the presence of maternally acquired anti-
HIV antibodies, a delay of BCG administration in newborns delivered 
by HIV-infected mothers should be carefully considered. Findings from 











this vaccination schedule (delay to 10 weeks) should be tested in HIV 
exposed but uninfected infants. 
 
1.8.3 Novel TB vaccines on the horizon 
Some vaccines have been shown to be effective through repeated 
administration with the same vaccine (homologous boost) (160-162). The 
protective immune response for such vaccines are mainly dependent on 
humoral immunity. In TB and other mycobacterial diseases, protective 
immunity is thought to be mainly dependent on cellular immunity and 
homologous boost has been shown to be ineffective (163, 164). Therefore, 
prime-boost heterologous vaccination strategy is considered an alternative. 
The principle of prime-boost heterologous vaccination strategy is to enhance 
antigen-specific primed immunity. The immunodominant antigens 85A, 85B 
and TB10.4 have been the primary target for boost following BCG priming. 
The majority of novel TB vaccines currently in advanced stage of clinical 
trials are designed to boost BCG-induced immunity (105, 106). The main 
novel TB boost vaccine candidate are protein-based and viral-based (165). 
 
Modification of the current BCG vaccine to make it more immunogenic is 
another approach in the development of better TB vaccines. Recombinant 
BCG (rBCG) vaccines, with increased expression of selected 
immunodominant antigens have shown promising results at preclinical stage 
(112, 166). Some rBCG have deletion of a gene encoding for urease in the 
parent BCG and integration of a gene encoding for listeriolysin (167) or 
perfringolysin (168). The listeriolysin or perfringolysin gene is associated with 
lysis of the endosome compartment within the infected cells allowing for 
enhanced MHC-I antigen presentation (169). Also, endosome escape is 
associated with induction of macrophage apoptosis; apoptotic cells are 
cross-presented resulting in enhanced immunity (170). If safety, 
immunogenicity and effectiveness data compares well against the parent 












Additional new TB vaccine approaches include inactivated whole 
mycobacteria or fragmented mycobacteria (165). New TB vaccines of 
inactivated M.vaccae as well as detoxified cellular M.tb fragments have 
already been tested in clinical trials; both have showed good safety profile 
(171, 172). In a randomized, placebo-controlled, double-blind trial involving 
HIV infected adults with a history of childhood BCG vaccination, 
administration of multiple shots of M.vaccae was shown to confer significant 
protection against TB (172). RUTI, a novel vaccine comprised of detoxified 
and liposomed cellular fragments of M.tb was shown to be safe and 
immunogenic in a phase 1 clinical trial conducted with healthy adults (171). 
Other vaccine design approaches at the preclinical stage include attenuation 
of M.tb (64) and naked DNA vaccines encoding mycobacteria antigens such 
as Ag85A and Ag85B (173). 
 
The global BCG vaccination coverage is over 80% (57) and the safety, 
effectiveness of BCG in preventing severe TB and other mycobacterial 
diseases in children is well established (125). Consequently, there are 
concerns that replacing BCG altogether may negatively interfere with its 
targeted and non-targeted benefits. It is therefore important to understand 
how BCG-induced immunity may be enhanced. Enhanced priming may result 
to optimal boosting and possibly increased effectiveness against TB. Studies 
in chapter five of this thesis evaluated whether a delay in BCG administration 
in infants may enhance the BCG-induced immunity. 
 
In summary, the new TB vaccines under development might exert their effect 
in several ways: (i) prevent initial infection (ii) prevent primary TB disease (iii) 
prevent establishment of latency (iv) prevent reactivation of latent infection or 
(v) shorten the course of disease and improve the response to chemotherapy 
(52). A holistic view of the vaccination strategies and their associated 
immune mechanisms thought to confer protection are shown in Figure 4. 
Table 1 provides a description of different types of novel TB vaccines 














Figure 4: Novel TB vaccine prime-boost vaccination strategies. TB vaccines may be 
preventative (to prevent M.tb infection), suppressive (suppress M.tb establishment after 
infection), prevent TB reactivation, or therapeutic. Vaccines may induce immune cells 
thought to be important in TB immunity, which include: (a) Th1 cells producing IFN-γ, TNF-α 
and IL-2, (b) Th17 cells producing IL-17, (c) Cytotoxic T lymphocytes (CTL) producing 
cytotoxic molecules. The Th2 cytokines and regulatory T cells (Tregs) may dampen the 
effector response. Another inhibitory mechanism of effector response is exhaustion of T cells 























rBCG prague strain expressing listeriolysin and 
carries a urease deletion mutation 
 
rBCG Tice strain expressing 30 kDa M.tb 
antigen 85B; phase I completed in U.S. 
Viral vector 
vaccine 







Modified vaccinia Ankara vector expressing 
M.tb antigen 85A 
 
Replication-deficient adenovirus 35 vector 
expressing M.tb antigens 85A, 85B, TB10.4 
 
Replication-deficient adenovirus 5 vector 













Adjuvanted recombinant protein composed of 
M.tb antigens 85B and ESAT-6 
 
Adjuvanted recombinant protein composed of 
M.tb antigens 85B and ESAT-6 
 
Recombinant protein composed of a fusion of 
M.tb antigens Rv1196 and Rv0125 & adjuvant 
 
Adjuvanted recombinant protein composed of 








Fragmented M.tb cells 
 
Inactivated whole cell non-TB mycobacterium; 
phase III in BCG-primed HIV+ population 
completed; reformulation pending  
 
Whole cell extract; phase I completed in China  
 
Table 1: Novel TB vaccine candidates in clinical trials in the year 2009. Stop TB Partnership 
website (174).  
 
 
1.9 Assays to measure tuberculosis vaccine take 
Bacillus Calmette-Guérin and novel TB candidate vaccines are aimed to 
mainly induce T cell immunity. Hence, immunological assays are designed to 
measure this type of vaccine-specific immunity. In humans, the majority of 
these assays evaluate the magnitude or quality of vaccine-specific memory T 
cells in the peripheral blood. Unlike lymph nodes, lung tissue and bronchial 
alveolar lavage, human peripheral blood is easier and less invasive to obtain 
hence suitable for these assays. Typically, most assays utilize in vitro 
restimulation of peripheral whole blood or peripheral blood mononuclear cells 











(175). At protein level, the responding cytokine-producing cells can be 
measured by Elisa, Elispot and flow cytometry, for example (176), while at 
molecular level, methods such as quantitative real time polymerase chain 
reaction (PCR) are routinely used (176). The choice of method to use largely 
depends on the selected outcomes of interest and the resources available. 
 
In TB vaccine clinical trials, whole blood or PBMC may be used when fresh, 
after cryopreservation or both. The duration of the immunological assay may 
also vary depending on practicalities and the nature of the question being 
addressed; (i) long-term assay (four or more days), (ii) medium-term assay 
(one to three days) or (iii) short-term assay (less than 24 hours) (175).  
 
Long and medium term assays measure the capacity of antigen experienced 
cells to proliferate and acquire effector activity (177). Proliferating cells may 
also be phenotyped in these assays, although incubation may change 
surface phenotypes. These assays are thought to be ideal to measure a Tcm 
response, as these cells may require longer stimulation for activation. 
Expansion allows for an increase in sensitivity of the measured response. 
These assays are less affected by the time to incubation of blood or isolated 
PBMC with antigens, compared with short term assays. Finally, long and 
medium term assays are less affected by the manipulation at PBMC isolation 
and cryopreservation, compared with short-term assays (175). Long- and 
medium term assays are labour and resource intensive, and may be 
vulnerable to contamination during the culture period. Long and medium term 
assays are labour and resource intensive, and may be vulnerable to 
contamination during the culture period. These results are semi-quantitative, 
reflecting phenotype and function of expanded cells – these phenotypes may 
not have been the same at the onset of the assay (175). The selection of a 
suitable assay depends on what is practical within the study settings. In this 
thesis, we chose to utilize short-term whole-blood assays for several 
reasons. First, a “snapshot” of immunity present at the time of blood 
collection, in an entire immune compartment (peripheral blood) is measured. 
Second, very small blood volumes are required, which is an important 











stimulation of whole blood increases sensitivity of the measured T-cell 
response, compared with stimulation of cryopreserved PBMC. Fourth, assay 
backgrounds are lower than those of PBMC-based assays, further increasing 
the sensitivity (178). 
 
Regardless of whether whole blood or PBMC is used, optimization of the 
chosen assay system is key in generating reliable immunological data. 
Resource permitting, performing a combination of short-, medium- and long-
term assays would yield more information. We used a short-term whole blood 
assay followed by intracellular cytokine staining (ICS) analysis on a PFC. 
The short-term whole blood assay was optimized using whole blood from 
adults and 10-week old BCG vaccinated infants (178). Every stimulation step 
of the assay for this application was evaluated and optimized (178). This 
assay is robust and delivers specific, sensitive, and reproducible results 
(intra-assay coefficients of variation of less than 10%). 
 
1.10 Contributions  
B.M.N.Kagina wrote this chapter with supervision by Prof. W.A. Hanekom 











Chapter 2: Long-term cryopreservation of stimulated adult whole blood 
does not affect detection of IFN-γ+-expressing CD4+ T cells as 
measured by an intracellular cytokine assay 
 
Results presented in this thesis were derived from examination of stimulated, 
fixed cells, obtained from whole blood incubated with specific antigens, and 
cryopreserved for long periods. Our first objective was to assess whether 
long-term cryopreservation would allow reliable measurement of 
mycobacteria induced immune responses. 
 
2.1 Background 
Our laboratory is involved in assessing immunity induced by novel TB 
vaccines and investigating immune correlates of risk/protection against TB. 
To date, thousands of infant, adolescent, and adult whole blood and PBMCs 
have been collected, processed and cyopreserved for analysis (179). 
Cryopreservation of cells is a common practice in clinical immunological 
studies that incorporate long follow-up periods, or which involve large sample 
sizes. In these settings, it is often impractical to complete assays in real time; 
moreover, in longitudinal studies, batch analysis of samples from individual 
participants is often preferred because of a reduction in variability of assay 
conditions. In addition, batch analysis is often more cost effective. 
 
Cryopreservation may be defined as the maintenance of biological samples 
in cold storage. Cells are typically stored at temperatures below −140°C. 
Mononuclear cells may be cryopreserved prior to stimulation; alternatively, 
these cells or whole blood may be incubated with specific antigens prior to 
cryopreservation. Cryopreservation of viable cells in specific media at very 
low temperatures may enable long-term preservation of many functional 
properties of the cells (180). 
 
The cryopreservation process begins with a stepwise reduction in 
temperatures (181). As the cells cool to temperatures between -5 to -15°C, 











across the cell membrane that causes osmotic stress, resulting in water 
being drawn out of the cells (180). Further reduction of temperatures leads to 
increased extracellular ice crystal formation, which can result in cellular 
injury, cell membrane shrinking, and ultimately a toxic increase in the 
concentration of intracellular solutes (180). The faster the cooling rate, the 
smaller the ice crystal formation and vice-versa (180). Very rapid cooling can 
minimize ice crystal formation almost completely resulting in vitrification of 
the solutes and increased cell viability (180); however, in practice, this is not 
fully achievable without cryoprotectants. The addition of cryoprotectants prior 
to cooling increases viscosity of the extracellular solution (180). 
Consequently, freezing point and ice crystal formation of the solution are 
lowered allowing vitrification temperatures to rise during the freezing process 
(180). This minimizes cellular injury during cryopreservation. Extensive 
progress has been made in the field of cryoprotectants (182). Dimethyl 
sulfphoxide (DMSO), glycerol and propylene glycol are the most commonly 
used cryoprotectant agents (180). 
 
For immunology studies, cryopreservation may be of viable PBMCs or of 
fixed cells from stimulated whole blood. The advantages of cryopreserving 
viable PBMCs include the following: multiple vials of cells may be frozen from 
the same donor allowing for repeat analysis, stimulation antigens can be 
conveniently introduced post-thawing, and viability markers are easily 
incorporated when performing functional assays. The disadvantages of 
cryopreserving PBMC include: large volumes of blood are required, viability 
may be compromised during the thawing process, and activation of caspases 
may occur leading to reduced cellular function (180, 182). 
 
Cryopreservation of fixed cells from stimulated whole blood is common in 
clinical trials with immunology components. Fresh whole blood is first 
incubated with selected antigens for a predefined period. Then, brefeldin A or 
monensin may be added to trap secreted cytokines intracellularly (183, 184). 
Red blood cells are then lysed and white blood cells harvested. Finally, the 
white blood cells are fixed with fixative agents followed by cryopreservation. 











paraformaldehyde (185). Fixative agents cause cross-linkage of cell 
membrane components allowing preservation of cell membrane integrity 
(186). This blocks penetration of high molecular weight compounds into the 
cell during cryopreservation. Assays performed with cryopreserved fixed cells 
from stimulated whole blood require smaller blood volumes, less resources 
(during stimulation steps), and are generally more sensitive than viable 
PBMC samples stimulated post-cryopreservation. A disadvantage of 
cryopreserving fixed cells from stimulated whole blood is that stimulations 
cannot be conducted retrospectively, which prevents flexibility later in the 
assay. 
 
Our aim in this chapter was to assess whether long-term cryopreservation of 
stimulated and fixed white cells affect the mycobacteria-induced immune 
response when measured by ICS assay. We hypothesized that BCG-, PPD- 
and SEB-induced CD4 T cell IFN-γ response is not reduced when fixed cells 
obtained from whole blood incubated with specific antigens is cryopreserved 
for long periods. We also evaluated the effects of prolonged cryopreservation 
on PBMC viability. 
 
2.2 Materials and methods 
2.2.1 Study participants and blood collection  
Healthy adults were recruited at the Institute for Infectious Diseases and 
Molecular Medicine of the University of Cape Town in South Africa. All 
participants had received BCG at birth and lived in the Western Cape 
Province of South Africa, a region with a very high incidence of TB disease 
(187). Study participation by all volunteers was approved by the University of 
Cape Town research ethics committee using the guidelines of the National 
Health Research Ethics Council. Good clinical practice guidelines were 
adhered to and this included written informed consent from the participants. 
For the short-term whole blood assay, 200mL blood was collected from each 
donor in heparinized tubes. For the PBMC isolation, 200mL blood was 















BCG Danish 1331 (Statens Serum Institut, Copenhagen) was prepared from 
the vaccine vial by reconstitution with RPMI and used at a final concentration 
of 1.2 x 106 CFU/mL of blood, a dose found optimal in preliminary 
experiments (178). Purified protein derivative (PPD, Statens Serum Institut, 
Copenhagen) was used at a final concentration of 10µg/mL and 
Styphylococcal enteroxin B (SEB, Sigma), a positive control, was used at a 
final concentration of 10µg/mL as previously described (178).  
 
2.2.3 Short-term whole blood stimulation and cryopreservation  
Tubes containing one mL whole blood volumes from each participant were 
either left unstimulated (negative control) or stimulated with BCG, PPD or 
SEB (positive control). The co-stimulatory antibodies anti-CD28 and anti-
CD49d (both from BD Biosciences, 1µg/mL) were included in all assay 
conditions. These co-stimulatory antibodies have been shown to enhance the 
specific cytokine response (178). The whole blood was incubated at 37°C for 
12 hours, and Brefeldin-A (Sigma, 10µg/mL) was added for the last five 
hours of incubation. The blood was then harvested with EDTA (Sigma, 2µM), 
red blood cells lysed and white cells fixed with FACS lysing solution (BD 
Biosciences). Later, white cells were pelleted and multiple aliquots per 
antigen/ condition per donor were cryopreserved in 10% DMSO (Sigma) in 
fetal calf serum (BioWest). 
 
2.2.4 Intracellular cytokine staining 
One week after phlebotomy, an aliquot of cryopreserved fixed cells from 
whole blood incubated with each of nil, BCG, PPD, and SEB was thawed at 
370C, cells were washed, permeabilized with perm/wash solution (BD 
Biosciences) and incubated for one hour with fluorescence-conjugated 
antibodies against intracellular IFN-γ and surface antigen CD4. The 











PE (25723.11), both from BD Biosciences. Flow cytometric acquisition was 
performed on a FACSCalibur (BD Biosciences) and at least 40,000 events 
were acquired. Subsequently, aliquots of the cryopreserved fixed cells were 
thawed and similarly processed at 3 monthly intervals. Flow analysis was 
performed using Flowjo software (9.0.2, TreeStar). 
 
2.2.5 PBMC isolation and cryopreservation 
PBMC were isolated using CPT (BD Biosciences). Immediately after 
isolation, viable recovery was assessed using trypan blue (Sigma) exclusion 
staining. For each participant, multiple cryovials containing 107 viable PBMC 
in 1mL 10% DMSO in fetal calf serum were step-frozen: vials were placed 
overnight in “Mr. Frosty” containers (Nalgene/Merck) containing isopropyl 
alcohol to allow step-wise freezing to -80°C. The foll wing morning, the vials 
were transferred into liquid nitrogen for long-term storage. 
 
2.2.6 PBMC thawing and viability  
At three month intervals and over a period of four years, cryopreserved 
PBMC were rapidly thawed at 37°C. When only a small ice pellet remained, 
RPMI containing 5% human AB serum (Western Province blood Transfusion, 
SA), (BioWhittaker) was added dropwise, with gentle shaking of the cryovial. 
The amount of medium added was doubled after each shaking. When the 
cryovial was full, the contents were transferred into a 15mL conical 
polypropylene tube (BD Biosciences), and medium was added dropwise to fill 
the tube. PBMC were washed twice before resuspension in medium, and  
viability determined by use of trypan blue exclusion stain. 
 
2.2.7 Data analysis  
The frequencies of IFN-γ+ CD4+ T cells over time, in the nil, BCG, PPD and 
SEB conditions were assessed for all the donors. The unstimulated values 
were subtracted from the BCG, PPD and SEB values. The coefficient of 
variation (CV) analysis was used to measure the variability in the median 
frequencies of IFN-γ+ CD4+ T cells over time. The viable PBMCs were 











CV analysis was used to measure the variability in the frequencies of viable 
PBMC for all the donors. The one way analysis of variance (ANOVA) test 
was used to assess whether the mean viable PBMC for all the donors over 
time were significantly different. P values less than 0.05 were considered 
significant. All the data was analysed using GraphPad Prism version 5.0a. 
 
2.3 Results 
2.3.1 Gating strategy for the whole blood intracellular assay 
We used the gating strategy shown in Figure 5 to measure the unstimulated 
and the mycobacteria-specific responses following long-term 
cryopreservation. This strategy enables exclusion of background 
autoflourescence and doublet cells, which would otherwise reduce the 
reliability of the results. 
 
 
Figure 5: Gating strategy. CD4+ T cells were first selected by gating CD4 against side 
scatter (SSC). We then used an exclusion gate comprising Forward Scatter (FSC) against 
the empty PerCP channel (A). An example of flow cytometric detection of IFN-γ expressing 
CD4+ T cells when whole blood was left unstimulated or following incubation with BCG, PPD 
or SEB, and costimulants (unstimulated), for 12 hours. Representative dot plots of IFN-γ 
expression in CD4+ T cells from unstimulated, BCG, PPD and SEB-stimulated conditions 











2.3.2 IFN-γ+ expression in CD4+ T cells from unstimulated blood does 
not increase following long-term cryopreservation 
In our laboratory, we have observed increased expression of intracellular 
cytokines in unstimulated PBMC that were frozen, thawed and incubated, 
compared with stimulation of PBMC immediately after isolation. In the whole 
blood assay, cells are fixed after stimulation, and later thawed for flow 
cytometric analysis. We wished to assess whether similar increases in 
unstimulated IFN-γ+ expression would be observed with the whole blood 
assay after cryopreservation. This IFN-γ+ expression was assessed one week 
after cryopreservation, and 3 monthly thereafter, up to 45 months later. We 
showed that in the majority of participants, background frequencies of IFN-γ+ 
CD4+ T cells remained within a narrow margin, and did not increase over 
time (Figure 6A-K). We concluded that cryopreservation did not result in 













Figure 6: Longitudinal background frequencies of IFN-γ+ in CD4+ T cells. For the 11 
donors analyzed (A-K), we utilized the gating strategy described in Figure 1 to measure the 
background (unstimulated) frequencies of IFN-γ+-expressing CD4 T cells from 1 week after 
cryopreservation, and 3 monthly thereafter, up to 45 months later. Samples from the majority 
of donors were analyzed at all time points, but only up to 18 months. Only 5 donors had their 
samples analyzed beyond the 3-year period. The dashed lines indicate values corresponding 




2.3.3 No change in the frequency of mycobacteria-specific IFN-γ+-
expressing CD4+ T cells following long-term cryopreservation of 
stimulated whole blood 
Next, we assessed whether frequencies of mycobacteria-specific IFN-γ+ 
CD4+ T cells changed following long-term cryopreservation of whole blood 











expression was assessed one week after cryopreservation, and 3 monthly 
thereafter, up to 45 months later. The frequencies of IFN-γ+ CD4+ T cells 
remained within a very narrow range (Figures 7A-K and 8A-K). We 
concluded that cryopreservation did not result in a change in the frequencies 













Figure 7: Longitudinal BCG-specific frequencies of IFN-γ  in CD4+ T cells. For the 11 
donors analyzed (A-K), we utilized the gating strategy described in Figure 1 to measure the 
BCG-specific frequencies of IFN-γ+-expressing CD4 T cells. Background (unstimulated) 
frequencies were subtracted from the respective BCG samples for the relevant time point 
analyzed. Analysis was performed from 1 week after cryopreservation, and 3 monthly 
thereafter, up to 45 months later. Samples from the majority of donors were analyzed at all 
time points, but only up to 18 months. Only 5 donors had their samples analyzed beyond the 
3-year period. The dashed lines indicate values corresponding to 30% variation relative to 












Figure 8: Longitudinal PPD-specific frequencies of IFN-γ  in CD4+ T cells. For the 11 
donors analyzed (A-K), we utilized the gating strategy described in Figure 1 to measure the 
PPD-specific frequencies of IFN-γ+-expressing CD4+ T cells. Background (unstimulated) 
frequencies were subtracted from the respective PPD samples for the relevant time point 
analyzed. Analysis was performed from 1 week after cryopreservation, and 3 monthly 
thereafter, up to 45 months later. Samples from the majority of donors were analyzed at all 
time points, but only up to 18 months. Only 5 donors had their samples analyzed beyond the 
3-year period. The dashed lines indicate values corresponding to 30% variation relative to 
the frequency of IFN-γ+ CD4+ T cells observed at one week after cryopreservation. 
 
 
2.3.4 No change in the frequency of SEB-induced IFN-γ-expressing 
CD4+ T cells following long-term cryopreservation of stimulated whole 
blood 
In intracellular cytokine staining assays, a positive control is critical for 











suboptimal responses, results from other conditions should not be included in 
data analysis. We assessed whether long-term cryopreservation would result 
in changes in IFN-γ+-expressing CD4+ T cells after SEB stimulation of whole 
blood. IFN-γ+ expression was assessed one week after cryopreservation, and 
3 monthly thereafter, up to 45 months later. We showed the frequency of 
SEB-induced IFN-γ+-expressing CD4+ T cells did not change significantly 
(Figures 9A-K). We concluded that there was no change in the frequencies 
of IFN-γ+ CD4+ T cells after SEB stimulation followed by longterm 
cryopreservation. However all donors displayed levels that fluctuated during 














Figure 9: Longitudinal frequencies of IFN-γ  in CD4+ T cells in SEB stimulated whole 
blood samples. For the 11 donors analyzed (A-K), we utilized the gating strategy described 
in Figure 1 to measure the frequencies of IFN-γ+-expressing CD4+ T cells following SEB 
stimulation of whole blood. Background (unstimulated) frequencies were subtracted from the 
respective SEB stimulated samples for the relevant time point analyzed. Analysis was 
performed from 1 week after cryopreservation, and 3 monthly thereafter, up to 45 months 
later.  Samples from the majority of donors were analyzed at all time points, but only up to 18 
months. Only 5 donors had their samples analyzed beyond the 3-year period. The dashed 
lines indicate values corresponding to 30% variation relative to the frequency of IFN-γ+ CD4+ 













2.3.5 Frequencies of mycobacteria-specific IFN-γ+ CD4+ T cells vary 
marginally following long-term cryopreservation 
To assess whether frequencies of unstimulated, mycobacteria-specific, and 
SEB-induced IFN-γ+ CD4+T cells are compromised following long-term 
cryopreservation of fixed white cells from stimulated whole blood, we 
evaluated the intra-donor variability of the unstimulated, BCG-, PPD-, and 
SEB-induced responses measured at different time points (median of 6 time 
points). The median CVs were 73.7, 15.5, 20.9, and 13.1% for unstimulated, 
BCG, PPD and SEB conditions,  respectively (Table 2). We concluded that 
the observed variations in the frequencies of mycobacteria-specific and SEB-
induced IFN-γ+ CD4+ T cells were within acceptable ranges following long 
term crypreservation. 
 
Coefficient of variation (%) 
Donor ID 
Number of time 
points analyzed Uns BCG PPD SEB 
A 11 94.6 8.5 16.9 11.8 
B 10 46.8 19.1 32.5 17.9 
C 6 77.3 38.3 19.7 9.4 
D 7 88.4 15.5 20.9 13.6 
E 6 86.1 9.6 12.6 4.9 
F 5 45.0 19.7 11.4 8.2 
G 6 73.7 40.3 22.6 13.5 
H 4 75.2 9.5 38.2 16.9 
I 14 59.9 10.6 23.8 13.1 
J 6 44.1 26.5 23.5 42.7 
K 8 52.1 15.3 16.3 11.2 
        
Median 6 73.7 15.5 20.9 13.1 
 
Table 2: Intra-donor coefficient of variation of the assay. Results are shown for intra-
donor CVs for frequencies of Unstimulated (Uns), BCG-, PPD-, and SEB-induced IFN-γ-
expressing CD4+ T cells for all the time points analyzed. Unstimulated responses were 
subtracted from the respective stimulated responses for each time point. The number of 
time points analyzed for individual donors are indicated. The minimum and maximum time 











2.3.6 Peripheral blood mononuclear cells viability is significantly 
reduced within the first week of cryopreservation, but appears stable 
during long-term cyostorage 
To assess the effects of long-term cryopreservation on the viability of PBMC, 
we assessed recovery of viable PBMC thawed 1 week after 
cryopreservation, and 3 monthly thereafter, for a period up to 48 months. We 
showed that the greatest reduction in viability occurred immediately after 
cryopreservation (p<0.0001), while the number of viable cells recovered at 
later time points remained remarkably similar (p>0.05 when any 2 time points 
were compared after 1 week. Figure 10). The average viablity during the 
cryopreservation period was >80%, a threshold level of 70% has been 
reported to be sufficient to perform optimum functional immunological assays 
(188). We concluded that long-term cryopreservation of viable PBMC is 
feasible in our setting. 
 
 
Figure 10: Longitudinal recovery of viable PBMC after cryopreservation. Viable PBMC 
recovery rate after thawing cryopreserved cells one week after cryopreservation, and at 3-
monthly intervals thereafter. Viability was determined by trypan blue exclusion. Mean and 













We report that the frequencies of change of IFN-γ+ CD4+ T cells detected by 
ICS assay are not compromised after long-term cryopreservation of 
stimulated, fixed cells, obtained from whole blood. We observed a significant 
reduction in the viability of PBMC after one week of cryopreservation, 
however at later time points, PBMC viability was maintained for up to 48 
months after cryopreservation. 
 
In biological assays, the CV is a measure of precision within or between 
repeated measurement values (188). In ICS assays, CVs of up to 30% may 
be considered acceptable (189). We observed CVs of <30% in the 
frequencies of antigen-specific IFN-γ+ CD4+ T cells. CVs of up to 23.6% have 
been previously reported in ICS assays using freshly processed and 
stimulated whole blood samples (189). It is therefore possible that the slightly 
higher CVs observed in our study may be due to ICS assay variability and 
not long-term cryopreservation. Batch variation in reagents used during the 
extensive period of the study (45 months), and variability introduced by 
multiple operators may also partly explain the observed CVs. The CVs for 
unstimulated samples were high (73.7%), which could be explained by the 
fact that the mean for IFN-γ+ CD4+ T cells was near zero, thus rendering the 
CV extremely sensitive to small changes. In these experiments, we chose to 
evaluate changes in the frequency of mycobacteria-specific IFN-γ+ CD4+ T 
cells because these cells are the most highly induced in our assay system. It 
is rational to assume that the variation or stability in this outcome could be 
valid to other cytokines. Therefore, repeatability in measurements of low 
magnitude frequencies with ICS may be unreliable.  
 
Our laboratory is highly experienced in flow cytometry analysis of  
mycobacteria-specific cytokine-expressing T cells, following long-term 
cryopreservation of stimulated, fixed cells, obtained from whole blood. We 
have observed a notable increase in the  autofluorescence of cells, which 
could be associated with long-term cryopreservation (unpublished 











minimize the detection of auto-fluorescing dead cells, which may affect the 
reliability of the results. Currently, there are viability cell dyes that can be 
used to stain whole blood before cryopreservation (190). Use of such viability 
dyes may exclude the dead cells and ultimately minimize autofluorescence 
and false-positive signals in the channels of interest. 
 
We observed stable frequencies of antigen-specific IFN-γ+CD4+ T cells in 
stimulated, cryopreserved fixed whole blood cells. The recovery of viable 
PBMC was significantly lower after one week of cryopreservation compared 
with all later time points. This indicated that ICS assays utilizing 
cryopreserved fixed cells from stimulated whole blood may be more suitable 
for our studies than cryopreserved PBMC. However, the decline in 
recoverable viable PBMC stabilized, and at least 80% viability was retained 
up to 48 months after cryopreservation. It is likely that the significant 
reduction in viability occurred during the overnight step freezing process and 
not later during the cryopreservation. Introduction and removal of 
cryoprotectants are critical steps in the maintance of viable cells (191). High 
PBMC viability is a key variable in the performance of immunological assays. 
When using cyopreserved PBMC stimulated with either cytomegalovirus 
(CMV) or pokeweed mitogen (PWM), Weinberg et al. reported that a 
minimum viability of 70% was optimal for functional immunological assays 
(188); PBMC samples with viable recovery of less than 70% showed 
inconsistent proliferative responses. Although different functional assays may 
have variable PBMC viability requirement for optimal performance, it is 
widely known that high viability is critical in assays utilizing fresh or 
cryopreserved PBMC. Knowledge on how long-term cryopreservation of 
biological samples may affect mmunological outcomes remains inadequate.  
A similar threshold of 70% in PBMC viability was reported to be critical for 
optimal proliferative T cell assays when cryopreserved PBMC were 
stimulated with tetanus toxoid (191). Incorporation of steps such as overnight 
resting of PBMC after thawing, and the use of a viability dye during analysis, 
greatly improves the functional capacity of T cells and minimizes detection of 












Anecdotal experience in some vaccine studies conducted in SATVI show that 
stimulation of viable PBMC after cryopreservation may result in reduced 
cytokine expression levels when measured in ICS assays. Furthermore, 
Costantini et al. reported that cryopreservation of PBMC derived from healthy 
adults resulted in reduced surface expression of CD62L on T cells, and this 
was accompanied by decreased proportions of naive and central memory T 
cell subsets while proportions of effector T cells was increased (192). The 
same study reported that CCR5 expression on T cells was reduced when 
PBMC from HIV-infected adults were cryopreserved and this was associated 
with reduced T cell proliferative capacity after stimulation with p24, an HIV 
derived antigen, CMV and Influenza virus (192). Such findings are not 
surprising because during cryopreservation, cell death can occur due to 
increased cellular stress (182) and temperature fluctuations may cause 
mechanical stress and cellular damage (182). Therefore, in addition to 
optimizing the cryostorage and thawing processes, maintenance of the 
cryofacility and stringent control of the cryostorage conditions is critical. To 
assess the effects of long-term cryopreservation on mycobacteria-specific T 
cells, stable conditions were observed during cryopreservation via a rigorous 
monitoring system implemented by our laboratory. With this monitoring 
system, fluctuations in cryotank temperatures and levels of liquid nitrogen in 
these tanks are monitored continuously. Corrective measures are in place to 
ensure that fluctuations do not compromise the integrity of the frozen 
samples. All the samples used for this thesis were stored in our cryofacility. 
 
In the period of 2002/3, SATVI collected stimulated whole blood and PBMC 
from more than 5,700 infants to determine correlates of risk of childhood TB 
disease development, following newborn BCG vaccination. All samples were 
cryopreserved in liquid nitrogen biobanks. Currently, several different studies 
are utilizing these samples to perform itracellular cytokine staining (ICS), 
proliferation and cytotoxicity assays. We conclude that implementation of 
optimized cryopreservation and thawing processes enables long-term 
cryostorage of stimulated whole blood and freshly isolated PBMC for 













Study design, sample collection and laboratory analysis was done by Prof. 
W.A. Hanekom and other members of SATVI laboratory. B.M.N. Kagina 
conducted data analysis and wrote this chapter under supervision of Prof. 











Chapter 3: Optimization of an 8-colour flow cytometric intracellular 
cytokine-staining assay to characterize BCG-specific T cells in infants 
 
3.1 Introduction 
In 2002/3, we designed a study to identify correlates of risk of childhood TB 
disease, following newborn BCG vaccination (Chapter four). This chapter 
focuses on the optimization of an 8-colour flow cytometric ICS panel to 
analyze the samples generated from this study. 
 
Flow cytometry is a widely applied technique of analyzing fluorescently 
labelled cells in fluidics channels (193). Both phenotype and functional 
characteristics of cells may be measured (193). Flow cytometers have 
evolved from three parameters, used in the late 1960s to more advanced 
polychromatic cytometers that could measure six parameters per cell in the 
1980s (194). In the 1990s, hardware, software and chemistry developments 
facilitated further technological advancements on polychromatic cytometers 
to measure more than ten parameters (194). Today, cytometers that can 
measure up to 20 parameters are available, allowing more complete and 
complex immunological analyses (193). Simultaneous analysis of a large 
number of parameters in a single cell using the advanced cytometers is 
commonly referred to as polychromatic flow cytometry (PFC). 
 
The advantages of PFC are multiple. For example, profiles of distinct 
antigen-specific T cell responses induced by a vaccine can be identified, 
based on functional (e.g cytokine) and phenotypic (e.g memory subsets) 
characteristics. Additionally, in pediatric study settings where limited volumes 
of blood samples are available, the use of PFC allows a researcher to obtain 
maximum information from small sample volumes. However, the benefits 
afforded by PFC are only achieved after meticulous optimization steps, more 
so when large polychromatic panels are utilized (195). These steps include:  
(i) selection of combinations of phenotypic and functional markers that may 
optimally be used together, (ii) optimal configuration of the flow cytometer, 
(iii) selection of optimal antibody-fluorochrome combinations, (iv) determining 











cytometer’s lower limit of detection, (vi) assessing spectral overlap by 
fluorescent minus one (FMO) controls, (vii) determining the intra-assay CV, 
and (viii) development of optimal gating strategy. 
 
This chapter describes how the optimization steps were rolled out to develop 
and optimize an 8-colour PFC panel. First, we describe how we utilized 
existing information to guide us in the design of optimization experiments. 
Second, in the results section of this chapter, we describe experiments that 
addressed the aforementioned technical challenges. The optimized PFC 
panel was used for studies described in chapter four and minor modifications 
of the panel were implemented for studies described in chapter five. 
 
3.1.1 Selection of phenotypic and functional markers 
Our broad aim is to identify correlates of risk of childhood TB disease, 
following newborn BCG vaccination. Our knowledge of immune correlates of 
protection against TB is inadequate. The following is a rationale for 
considering inclusion of the following 10 markers in the panel: CD3, CD4, 
CD8, gamma delta (γδ)T, IFN-γ, IL-2, TNF-α, IL-13, IL-17 and IL-22. 
 
We know that CD4 and CD8 T cell immunity is important for controlling 
progression of M.tb infection to TB disease (196, 197), and this kind of 
immunity is therefore the most commonly measured when evaluating 
mycobacterial immunity, and when assessing the immunogenicity of novel 
TB vaccines (105, 106). We also know that BCG mainly induces a Th1 
response (130). 
 
We considered measuring γδ T cells for the following reasons. In a clinical 
setting, it has been shown that PBMC derived from BCG vaccinated adults 
have a higher γδ T cell response compared with PBMC derived from BCG 
unvaccinated controls, upon in vitro restimulation with M.tb whole lysate, with 
BCG, or with the phosphoantigen isoprenyl pyrophosphate (IPP) (198). γδ T 
cells have been reported to express more IFN-γ in swine newborns 











setting, it has also been shown that γδ T cells and immature DC can bi-
directionally activate each other via CD1c surface molecule interaction, 
resulting in maturation of the DCs (200). The same study reported that the 
presence of both LPS and CD1-restricted γδ T cells was important to drive 
maturation of DCs with concomitant production of IL-12 and increased 
differentiation of naive T cells to Th1 cells (200). This observation implies an 
indirect association between γδ T cells and the induction of anti-
mycobacterial CD4 and CD8 T cells. 
  
As regards selection of cytokines, evidence suggesting increased incidence 
and severity of mycobacterial disease in human immune deficiencies from 
IFN-γRI+II-, IL-12Rβ1-, IL-12p40-, Stat1 (201-203) or acquired HIV infection 
(204, 205), have emphasized the critical role of conventional Th1 cells 
producing IFN-γ. There is data supporting the role of IL-2 in the maintenance 
and differentiation of T and NK cells (206, 207). These two subsets (T and 
NK cells) have crucial roles in TB immunity (197, 208). TNF-α has been 
reported to play a protective role in TB immunity. Observations that patients 
with rheumatoid arthritis and treated with anti-TNF-α monoclonal antibody 
were at increased risk of TB reactivation highlighted the crucial role of this 
pro-inflammatory cytokine (209). TNF-α knock out mice are not only more 
susceptible to M.tb infection and development of TB than wild type mice but 
also have poorly formed granuloma structures in the lungs (210). This 
suggests a possible role of TNF-α in the formation and maintenance of 
granuloma, structures presumed to help contain M.tb infection within the 
host. We postulated that BCG-induced Th1 immunity would correlate with 
reduced risk of TB disease development. In a short-term whole blood assay, 
our laboratory has shown that BCG-specific Th1 cells are readily 
measureable in 10-week old infants, routinely vaccinated with BCG at birth 
(130). We therefore included IFN-γ, IL-2 and TNF-α in our panel. 
 
In clinical and experimental studies, it has been shown that Th2 cells 
producing IL-4, IL-5 and IL-13, may dampen presumably protective vaccine-











specific Th2 cells. However, using a similar assay system, our group 
previously demonstrated that the T cell intracellular expression levels of IL-4 
and IL-5 were too low to allow for reliable analysis in BCG vaccinated 10-
week old infants (130). Thus, we considered including IL-13 in the panel, but 
not the other 2 cytokines (see below).  
 
Studies in our laboratory have shown mycobacterial-specific IL-17 and IL-22 
cytokine producing CD4 T cells in peripheral blood of healthy adults exposed 
to mycobacteria (212). Both IL-17 and IL-22 have been shown to display 
proinflammatory activity (213). Th17 cells may mediate protection against TB 
via IL-17-induced neutrophil recruitment, which produce chemokines for 
recruitment of protective Th1 cells (214). IL-22 producing cells have been 
demonstrated to be essential for effective host defence against bacterial 
infections (215). A study by Dhiman et al. reported that M.tb growth in human 
macrophages was restricted by IL-22 producing cells via enhanced 
phagolysosomal fusion (216). We therefore included IL-17 and IL-22 in our 
panel. Table 3 shows a summary and hypothesized roles of the immune 




Function Target cells 
IFN-γ -Activation of macrophages for control 
of intracellular M.tb 
-Macrophages 
-T cells 
IL-2 -Maintenance and differentiation of T 
and NK cells 
-Memory T cells 
TNF-α -Formation and maintenance of 
granuloma structures 
-Macrophage 
IL-17 -Recruitment of neutrophils and 






IL-22 - Limits M.tb growth in macrophages 
by enhanced phagosome and 
lysozyme fusion  
-γδ T cells 
-Macrophages 
IL-13 -Control of the effector response 





Table 3: Summary of the immune parameters selected as candidate immune correlates of 












3.1.2 Configuration of the flow cytometer 
We aimed to measure the 10 selected phenotypic and functional markers 
with a BD LSRII flow cytometer. Our instrument comprises 3 lasers and 14 
detectors: Red (3 detectors), Blue (8 detectors) and Violet (3 detectors). This 
configuration facilitates the assessment of a PFC panel that incorporates up 
to 12 parameters (excluding the side scatter (SCC) and forward scatter 
(FSC). The detectors and filters for the cytometer are configured to measure 
light emission of different fluorochromes. Each fluorochrome has a distinct 
emission spectrum detectable by a predefined detector; this can be exploited 
for polychromatic analysis.  
 
Fluorochrome brightness index score (BIS), a relative indication of 
fluorescence intensity above the background (1=dim, 5=brightest) is an 
important variable to consider when designing PFC panels. For example, 
highly expressed markers are easily resolved when stained with antibody-
fluorochrome conjugates of low BIS whereas, lowly expressed markers need 
to be conjugated to fluorochromes of high BIS to be clearly resolved. 
Detailed settings of the cytometer and fluorochrome BIS are provided in 
Table 4. We carefully considered these settings in the selection of optimal 
antibody-fluorochrome combinations during our optimization experiments, 
























































































Alexa Fluor 700 





Table 4: BD LSR II configuration and fluorochrome brightness index score: The LSR II 
has 3 lasers and 14 detectors. Each detector has a filter; long pass (LP) and band pass (BP) 
that determine the wavelength at which the fluorochrome emission signal is optimally 
detected. Fluorochromes that may be used for the different detectors and their associated 
BIS are also indicated (1=dim, 5=brightest). The BIS for PE-Texas Red, QDots-655 and -605 
are not reported (NR) (http://www.ebioscience.com/ebioscience/appls/Dyes.htm). 
 
 
3.2 Materials and Methods 
3.2.1 Short-term whole blood stimulation and cryopreservation  
To optimize our 8-colour ICS panel, we used an assay system previously 
developed in our laboratory (178). In the assay, whole blood is stimulated 
either with BCG, or SEB (positive control) or left unstimulated (negative 
control). To all assay conditions, co-stimulatory antibodies of anti-CD28 and 
anti-CD49d (both from BD Biosciences) are added at a final concentration of 
1µg/mL (178). The whole blood is incubated at 37°C for 12 hours, and 
Brefeldin-A (10µg/mL, Sigma) is added for the last 5 hours of incubation to 
capture cytokines intracellularly. Upon completion of incubation, the whole 
blood is harvested with EDTA (2µM, Sigma). Subsequently, red blood cells 
are lysed and white cells fixed with FACS lysing solution (BD Biosciences). 
The white cells are then pelleted, followed by cryopreservation in 10% DMSO 













Bacillus Calmette-Guérin (BCG, Danish 1331, Statens Serum Institut, 
Copenhagen) was prepared from the vaccine vial by reconstituting with 
RPMI, and is used at a final concentration of 1.2 x 106 CFU/mL. This dose 
was shown to be optimal in earlier experiments (178). Streptococcal 
enterotoxin B (SEB, Sigma), a positive control, is used at a final 
concentration of 10 µg/mL. 
 
3.2.3 Study participants and blood collection  
Healthy adults were recruited at the University of Cape Town, South Africa. 
Healthy 10-week old infants who had received BCG vaccine at birth were 
recruited at SATVI’s Worcester clinical site. The protocol was approved by 
the University of Cape Town Research Ethics Committee, and study conduct 
was guided by good clinical practice guidelines; this included written 
informed consent from the participants. Mothers gave consent on behalf of 
their infants. From each adult donor, 16 mL blood was collected in 
heparinized tubes. From each healthy infant, 8 mL blood was collected in 
heparinized tubes. After collecti n, blood was immediately transferred into 
pre-prepared tubes containing co-stimulatory antibodies with or without 
antigens. The blood stimulation and cryopreservation processes are 
described above.  
 
3.2.4 Intracellular cytokine staining assay and flow analysis 
The analysis of fixed white blood cells involves ICS and analysis by PFC.  
The following optimisation steps were addressed: 
• Optimal antibody-fluorochrome combinations 
• Optimal PMT voltage 
• The flow cytometer’s lower limit of detection  
• Fluorescence minus one (FMO) 
• Intra-assay coefficient of variation 
• Optimal gating strategy 
• Pilot studies with samples from healthy adult volunteers  











• T cell event counts in samples from healthy 10-week old infants 
• Minimum T cell numbers for reliable analysis of samples from healthy 
10-week old infants 
 
3.3 Results 
3.3.1 Optimal antibody-fluorochrome combinations 
Previously, our laboratory has tested combinations of the following 
fluorochrome-antibodies: CD3-Pac Blue, CD4-Cy5.5PerCP, CD8-FITC, CD8-
APC, CD8-Pac-Orange, CD8-Cy5.5PerCP, CCR7-APC, CD45RA-Cy7PE, IL-
13 FITC, IL-2-FITC, IL-2-Alexa610 PE, IFN-γ Alexa 700, TNF-α-Cy7PE, IL-
17-PE, IL-17-Alexa 647, IL-22-PE, IL-22-APC and γδTCR-APC (130, 178, 
212). Additional experiments for selection of the final panel are presented 
here. 
 
3.3.1.1 BCG-induced expression of IL-13, IL-17 and IL-22 
For inclusion in the panel, we wished to ensure that expression of the 
cytokine was of sufficient magnitude for detection within our whole blood 
assay system. Our first aim was to measure the frequencies of BCG-induced 
IL-13, IL-17 and IL-22 expressing T cells in whole blood from BCG-
vaccinated infants, incubated with BCG for 12 hours. Unlike IFN-γ, TNF-α 
and IL-2, our laboratory had not previously measured IL-13, IL-17 and IL-22 
in infants using this assay system. We first measured BCG-induced IL-13 
frequencies using a 4-colour panel: CD3-PacBlue, CD4-Cy5.5PerCP, CD8-
APC and IL-13-FITC. We then measured the frequencies of BCG-induced IL-
17 and IL-22 using a 5-colour panel: CD3-PacBlue, CD4-Cy5.5PerCP, CD8-
FITC, IL-17-Alexa 647 and IL-22-PE. The median frequency for BCG-
induced IL-13+CD4+ was 0.01% (n=6, Figure 11), whereas the median 
frequencies for BCG-induced IL-17+ CD4+ and IL-22+CD4+ were 0.021% and 
0.024%, respectively (n=5, Figure 12). We concluded that BCG-induced IL-
13+ CD4+ T cell frequencies were too low, both in infant and adult (data not 
shown) samples, to yield statistically realiable data for analysis, given 
anticipated cell numbers available for analysis. BCG-induced IL-17+ CD4+ 















Figure 11: Frequency of BCG-induced IL-13+ CD4+ T cells in infants. Whole blood from 
six 10-week old infants was stimulated with BCG for 12 hours, red blood cells lysed, white 
cells fixed, followed by cryopreservation. An ICS assay was performed to determine the 
BCG-induced frequencies of IL-13 in CD4+ T cells. Backgrounds were subtracted from the 




Figure 12: Frequencies of BCG-induced IL-17+ and IL-22+ CD4+ T cells in infants. 
Whole blood from five 10-week old infants was stimulated with BCG for 12 hours, red blood 
cells lysed, white cells fixed, followed by cryopreservation. An ICS assay was performed to 
determine the BCG-induced frequencies of IL-17 and IL-22 in CD4+ T cells. Backgrounds 












3.3.1.2 IL-22-PE exclusion  
Antibody batch variation may greatly affect staining profiles even though the 
supplier and clone remain unchanged. After using an old IL-22-PE antibody 
for the BCG-induced IL-22 experiments described above (Figure 12) (this 
antibody had been previously titrated), we ordered a fresh vial of IL-22-PE 
antibody. IL-22-PE antibodies from the fresh and old vials (both clone 
142928) from R&D systems were utilized for staining and the outcome 
compared directly.  Adult BCG-stimulated whole blood cells were stained 
with CD3-PacBlue, CD4-Cy5.5PerCP, CD8-FITC and IL-22-PE (old and 
new). Although both antibodies were stored under similar conditions, staining 
with the fresh IL-22-PE antibody vial revealed a high background frequency 
of 0.121%, compared to a background frequency of 0.037% after staining 
with the old IL-22-PE antibody vial (Figure 13). We c ncluded that the use of 
different IL-22-PE antibody vials may compromise analysis of IL-22, and 
therefore excluded this marker from further analysis. Although both 
antibodies were stored under similar conditions, staining with the fresh IL-22-
PE antibody vial revealed a high background frequency of 0.121%, 
compared to a background frequency of 0.037% after staining with the old IL-
22-PE antibody vial (Figure 13). We concluded that the use of different IL-
22-PE antibody vials may compromise analysis of IL-22, and therefore 
excluded this marker from further analysis. Although more experiments 
would have been appropriate to confirm the variability in staining with the IL-
22-PE antibody, we chose not to because the role of IL-22 cytokine in TB 
immunity remains poorly defined. As we had another flow cytometric channel 
available for analysis, we chose to assess γδ T cells because a role for these 
cells in host responses to TB is relatively well established (200). The anti-γδ 














Figure 13: IL-22-PE antibody staining. Whole blood from an adult volunteer was left 
unstimulated or stimulated with BCG for 12 hours, and Brefeldin-A added in the last 5 hours 
to capture intracellular cytokines. The ICS assay was performed to directly compare new 
and old IL-22-PE Abs. For flow analysis, singlets cells were first selected, then 
lymphocytes, and finally CD3+ T cells were differentiated into CD4+ and CD8+ T cells. We 




3.3.1.3 IL-2-Alexa 610PE exclusion  
We evaluated the compatibility of the IL-2-Alexa 610 PE antibody in our 
proposed PFC panel. Our laboratory had previously observed spectral 
overlap between Cy5.5PerCP and Alexa 610 PE. The overlap may however 
vary with the antibody-fluorochrome combinations included in the panel. We 
used unstimulated and stimulated fixed whole blood derived from an adult 
volunteer, and stained the samples with CD3-PacBlue, CD4-Cy5.5PerCP, 
CD8-FITC, and IL-2-Alexa 610 PE. We noted a high compensation between 
Cy5.5PerCP and Alexa 610 PE, which resulted in large data spread (Figure 











interest. We therefore excluded this antibody-fluorochrome combination from 
our proposed panel.  
 
 
Figure 14: IL-2-Alexa 610 PE antibody staining. Whole blood sample derived from an 
adult volunteer was left unstimulated, stimulated with BCG or SEB for 12 hours, and 
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines. The ICS assay 
was performed with CD3-Pac Blue, CD4-Cy5.5PerCP, CD8-FITC and IL-2-Alexa 610 PE. 
For flow analysis, singlets cells were first selected and then lymphocytes. Thereafter, we 
selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells.  
 
 
3.3.1.4 IL-2-FITC inclusion  
Next, we aimed to evaluate whether the IL-2-FITC antibody would be 
compatible with our proposed PFC panel. We used unstimulated and 
stimulated fixed whole blood cells derived from an adult volunteer and 
stained the cells with CD3-PacBlue, CD4-Cy5.5PerCP, CD8-Qdot 605, and 
IL-2-FITC. We did not observe any data spread when IL-2-FITC was 
evaluated against CD4-Cy5.5PerCP (Figure 15). We therefore included this 














Figure 15: IL-2-FITC antibody staining. Whole blood sample derived from an adult 
volunteer was left unstimulated, stimulated with BCG or SEB for 12 hours, and Brefeldin-A 
was added in the last 5 hours to capture intracellular cytokines. The ICS assay was 
performed with CD3-Pac Blue, CD4-Cy5.5PerCP, CD8-Qdot 605 and IL-2-FITC. For flow 
analysis, singlets cells were first selected and then lymphocytes. Thereafter, we selected for 
CD3+ T cells from which we selected CD4+ and CD8+ T cells.. 
 
 
3.3.1.5 CD8-QDot 605 inclusion 
Next, we decided to directly compare the outcome after staining with two 
candidate antibodies: CD8-Pac Orange and CD8-QDot 605. In our previous 
experiments, we had successfully used CD8-FITC and CD8-APC antibodies. 
However, we wished to use the bright FITC and APC fluorochromes for IL-2 
and γδTCR, respectively. The IL-2-FITC and γδTCR-APC antibodies had been 
previously tested in a different panel in our laboratory (212). To compare 
CD8-Pac Orange and CD8-QDot 605 antibodies, we first titrated a newly 
introduced CD8-QDot 605 antibody. It is important to titrate new antibody-
fluorochrome combinations to ensure that the chosen antibody concentrations 
yield an optimal signal compared with background noise, and have reached a 
saturation point (195). Antibody concentrations that are too low result in 
suboptimal signal. Antibody concentrations that are too high are wasteful and 
expensive, and may result in non-specific binding of the antibody and 
consequently false positive results. We used BCG-stimulated whole blood 
from an adult participant for the titration experiment. Six different CD8-QDot 
605 antibody concentrations were evaluated. The signal to noise (S/N) ratio, a 
measure of the signal intensity was computed for all the titration volumes 
used (Figure 16). We concluded that the 0.63µL (0.0063µM/mL) antibody 











ratio with the lowest titer volume. Below the optimal chosen titer volume, the 
S/N ratio starts getting lower. Similar optimal titer volumes were noted for the 
CD4-QDot 605 antibody.  
 
 
Figure 16: CD8-QDot 605 antibody titration plots. Six different CD8-QDot 605 antibody 
titer volumes were evaluated using BCG-stimulated whole blood derived from an adult 
volunteer and stained with CD3-Pac Blue, CD4-Cy5.5PerCP and CD8-QDot 605. For flow 
analysis, singlets cells were first selected and then lymphocytes. Thereafter, we selected for 
CD3+ T cells from which we selected CD4+ and CD8+ T cells. The MFI of CD8+ (signal) and 
CD8- (noise) T cells was assessed at different antibody concentrations (A). The optimal titer 














After establishing the optimal titration volume for CD8-QDot 605, we titrated 
CD8-Pac Orange (Figure 17), and then proceeded to compare resolution of 
the CD8 T cell subset after staining with either CD8-Pac Orange or CD8-
QDot 605 antibodies in our proposed PFC panel. Staining for markers 
conjugated with brighter fluorochromes such as PE, APC, Cy7PE and QDots, 
result in better separation of negative and positive cell populations. We 
stained adult BCG-stimulated whole blood cells with CD3-Pac Blue, CD4-
Cy5.5PerCP and CD8-QDot 605 or CD8-Pac Orange. The CD8-QDot 605 
antibody showed a brighter staining that easily resolved the CD8+ and CD8- 
cell populations. The CD8-Pac Orange antibody showed a dim staining with 
poor separation of the CD8+ and CD8- T cell populations (Figure 18). We 
therefore excluded CD8-Pac Orange, and rather selected CD8-QDot 605 














Figure 17: CD8-Pac Orange antibody titration plots. Five different CD8-Pac Orange 
antibody titer volumes were evaluated using BCG-stimulated whole blood derived from an 











For flow analysis, singlets cells were first selected and then lymphocytes. Thereafter, we 
selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. Curves for the 
signal to noise ratio (MFI of CD8+ as the signal and CD8- as the noise ) (B) and frequencies 
of CD8+ T cells (C), against titration volumes were generated. The 2µL and 5µL volumes 
appeared optimal and were further tested in a full 8-colour panel. The 5µL volume gave a 





Figure 18: CD8-QDot 605 and CD8-Pac Orange staining. Whole blood sample derived 
from an adult volunteer was stimulated with BCG for 12 hours and stained with CD3-PacBlue, 
CD4-Cy5.5PerCP, CD8-Qdot 605 or CD8-Pac Orange. For flow analysis, singlets cells were 
first selected and then lymphocytes. Thereafter, we selected for CD3+ T cells from which we 
selected CD4+ and CD8+ T cells. The CD8-Qdot 605 antibody stain was bright and resulted in 
clearly resolved CD8+ and CD8- T cells (left plot). The CD8-Pac Orange antibody stain was 
dim and resulted in poorly resolved CD8+ and CD8- T cells (right plot). 
 
 
3.3.1.6 Final antibody-fluorochrome combination  
Our next aim was to select the final antibody-fluorochrome combinations. We 
chose CD3-PacBlue, CD4-Cy5.5PerCP CD8-QDot 605, γδT-APC, TNF-
Cy7PE, IFN-γ-Alexa 700, IL-2-FITC and IL-17-PE antibody-fluorochrome 













Analyte Detector Fluorochrome  Manufacturer Cat.No 
CD3  Violet, C Pac Blue BD 558117 
CD4 Blue, C Cy5.5PerCP BD 332772 
CD8 Violet, B QDot 605 Invitrogen Q10009 
γδTCR Red, C APC BD 555718 
TNF-α  Blue, A  Cy7PE BD 557647 
IL-2 Blue, F FITC BD 340448 
IFN-γ Red, B Alexa Fluor 700 BD 544699 
IL-17 Blue, E PE EBioscience 12-7178-71 
 
Table 5: Detailed description of the antibody-fluorochrome combinations for the final panel 
and the detectors on the LSR II cytometer for assessing the markers. Manufacturer’s names 












3.3.2 Optimal photomultiplier tube (PMT) voltage 
3.3.2.1 Evaluating the baseline PMT settings 
Next, we aimed to establish the optimal PMT voltages for the channels in our 
final panel. Optimal PMT voltages ensure the fluorescence signal that is 
detected allows for maximum resolution for antibody staining (217). Lower 
than optimal PMT voltage results in stained markers of interest falling below 
the scale, while higher voltage results in the markers being off the scale. To 
establish the optimal PMT voltages, we first used 6 peak 3.0-3.4mM 
spherotech rainbow calibration particles (BD Biosciences). These particles 
fluoresce in all channels of LSR II cytometer (218). For each channel in our 
final PFC panel, we measured the coefficient of variation (CV, as a %) of the 
fluorescence of these particles at different PMT voltages (350-800). We then 
graphed the CV against the PMT voltages. On the graph, the baseline 
voltage was determined by selecting the lowest voltage where the CV 
showed stability. The baseline voltages for blue laser channels were: 450 for 
Cy5.5PerCP, 500 for both Cy7PE and PE, and 450 for FITC (Figure 19A). 
Baseline voltages for the red laser channels APC and Alexa Fluor 700 were 
500 and 450, respectively (Figure 19B). The baseline voltages for the violet 
laser channels were 450 and 400 for QDot 605 and Pac Blue, respectively 
(Figure 19C). These voltages were later evaluated for optimal resolution by 
use of unstained cells and single stained mouse kappa compensation beads. 
We successfully established baseline voltages that showed minimal CV in 
















Figure 19: Baseline PMT voltages for the channels assessed. In a 5mL falcon tube, 1mL 
of sheath fluid was added followed by a single drop of 6 peaks 3.0-3.4mM spherotech 
rainbow calibration particles. The mixture was vortexed and acquired on an LSR II cytometer 
at different PMT voltage settings (350 to 850). For each channel, we selected a single peak 
on the extreme left of the fluorescence plot when the PMT voltage was lowest. The 
fluorescence CV (%) for the peak was recorded at different PMT voltage settings for the blue 
laser (A), red laser (B) and violet laser (A). The arrows on the plots are examples to show the 











3.3.2.2 Establishing the final PMT settings 
The second step in PMT voltage optimization was to evaluate and adjust the 
selected baseline voltages to give an on scale negative (unstained) and 
positive (antibody stained) signal. Generally, a negative population should lie 
within the first decade of the x-axis scale. To adjust the baseline voltages, we 
used BCG-stimulated and fixed whole blood cells from a single adult 
participant. We then used the adjusted voltages to assess the negative and 
positive resolution of anti-mouse kappa-comp beads (BD Biosciences), 
labelled with the specific fluorochrome-conjugated antibodies for the 8-colour 
panel. Using unstained cells, we selected for lymphocytes and adjusted the 
voltages to give an on scale signal for the blue laser (Figure 20A), red laser 
(Figure 20B) and violet laser (Figure 20C). The adjusted voltages were then 
evaluated on single stained anti-mouse kappa compensation beads: blue 
laser (Figure 21A), red laser (Figure 21B) and violet laser (Figure 21C). We 
established that the optimal voltages were: 650 for both Cy5-5PerCP and 
Cy7PE-A, 500 for PE, 620 for FITC  (blue laser), 600 for both APC and Alexa 
Fluor 700 (red laser), 550 for QDot 605 and 450 for Pac Blue (violet laser). 
We concluded that the selected voltages were optimal to provide maximum 














Figure 20: Final PMT voltage settings I. Whole blood from an adult volunteer was 
stimulated with BCG for 12 hours. For flow analysis, no antibody staining was performed.  
Lymphocytes were selected by forward scatter-area (FSC-A) against side scatter-area (SSC-
A). For each channel of our 8-colour panel, PMT voltages were adjusted to the established 
baseline settings. The PMT voltages were then adjusted to allow for the unstained 
lymphocytes to fall within the first and second decade of the scale for the blue laser (A), red 













Figure 21: Final PMT voltage settings II. In eight separate 5mL falcon tubes, single drops 
of negative and positive anti-mouse kappa compensation beads were added. To each of the 
tubes, the established antibody staining volumes for CD3-PacBlue, CD4-Cy5.5PerCP CD8-
QDot 605, γδT-APC, TNF-Cy7PE, IFN-γ-Alexa 700, IL-2-FITC and IL-17-PE were added 
separately. For flow analysis, the bead population were selected by forward scatter-area 
(FSC-A) against side scatter-area (SSC-A). For each antibody staining, PMT voltages were 
adjusted to the final PMT voltage settings established using the unstained cells. The final 
PMT voltage settings showed distint negative and positive beads population for the blue laser 
(A), red laser (B) and violet laser (C). 
 
 
3.3.3 The lower limit of detection for the LSR II flow cytometer 
The next step was to establish the lower limit of detection for BCG-induced 
IFN-γ, TNF-α, IL-2 and IL-17, when measured with our LSR II cytometer. The 
cytometer’s lower limit of detection is defined as a limit below which the 
reliability of measuring the true value is compromised. We used fixed cells 
from BCG-stimulated whole blood sample from an adult. The stimulated cells 
were serially diluted with autologous unstimulated cells up to 4096-fold. We 











BCG-induced CD4 T cell cytokine expression. The background 
(unstimulated) frequencies were subtracted from the BCG-induced 
frequencies (represented as observed frequencies in Tables 6-9 below). 
Expected frequencies were obtained by dividing the undiluted BCG-induced 
frequencies with the dilution fold. The lower limit of detection for BCG-
induced cytokines was evaluated by calculating the magnitude of deviation 
for the observed from expected values using the following formula: 
 
(Expected x dilution factor) - (Observed x dilution factor) x 100% 
(Expected x dilution factor) 
 
Deviations ≥ 30% were considered large enough to compromise the reliability 
of the cytometer. We found that the cytometer’s lower limit of detection for 
IFN-γ and IL-2 was about 0.04% (Tables 6 and 8). The lower limit of 
detection for TNF-α and IL-17 was approximately 0.01% (Tables 7 and 9), 
respectively, suggesting that these cytokines could be reliably measured to 
vary below 0.01%. We also report that the sensitivity of the cytometer 
decreased as the dilution factor increased (Figures 22A to D). We used a 
short-term whole blood assay with infants’ samples to show that median 
frequencies of BCG-induced T cell IFN-γ, IL-2 and TNF-α are approximately 
0.1%. In earlier BCG-induced cytokines expression experiments, we 
established the frequencies of BCG-induced T cell IL-17 were approximately 
0.02%. We therefore concluded that the frequencies of BGC-induced T cells 
cytokines selected in the 8-colour PFC panel are over the limit of detection 













Observed  Expected  
Observed x 
dilution fold  
Expected x 




(%) Dilution fold 
1.428  1.428  1.428  1.428  0.00 1 
0.618  0.714  1.236  1.428  13.45 2 
0.328  0.357  1.312  1.428  8.12 4 
0.168  0.179  1.344  1.428  5.88 8 
0.073  0.089  1.168  1.428  18.21 16 
0.041  0.045  1.312  1.428  8.12 32 
0.030  0.022  1.920  1.428  34.45 64 
0.016  0.011  2.048  1.428  43.41 128 
0.010  0.006  2.560  1.428  79.27 256 
0.005  0.003  2.560 1.428  79.27 512 
0.009  0.001  9.216 1.428  >100 1024 
0.004  0.001  8.192  1.428  >100 2048 
0.004  0.000  16.384  1.428  >100 4096 
 
Table 6: Assessment of the LSR II limit of detection for IFN-γ+CD4+.  Whole blood from an 
adult volunteer was left unstimulated or stimulated with BCG for 12 hours, and Brefeldin-A 
was added in the last 5 hours to capture intracellular cytokines. The BCG sample was serially 
diluted with the unstimulated sample up to 4096-fold. The ICS assay was performed with the 
full 8-colour panel. For flow analysis, singlets cells were first selected and then lymphocytes. 
Thereafter, we selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. The 
frequencies of BCG-induced IFN-γ+CD4+ was analyzed and corrected for background levels 
to give the observed frequencies. The observed frequencies in the undiluted sample was 
presumed to be the same as expected frequencies in the same sample. Subsequently, 
expected frequencies in the diluted samples were calculated by dividing the expected 
frequencies in the undiluted sample with the dilution fold. Then, the observed and expected 
frequencies were multiplied by the dilution fold and the percentage deviation between the two 
frequencies calculated. Deviations  ≥  30% were indicative of loss of senstivity to detect the 

















Observed  Expected  
Observed x 
dilution fold  
Expected x 




values (%) Dilution fold 
0.659 0.659 0.659 0.659 0.000 1 
0.249 0.329 0.498 0.659 24.43 2 
0.149 0.165 0.596 0.659 9.56 4 
0.083 0.082 0.664 0.659 0.76 8 
0.031 0.041 0.496 0.659 24.73 16 
0.020 0.021 0.640 0.659 2.88 32 
0.010 0.010 0.640 0.659 2.88 64 
0.009 0.005 1.152 0.659 74.81 128 
0.005 0.003 1.280 0.659 94.23 256 
0.003 0.001 1.536 0.659 >100 512 
0.003 0.001 3.072 0.659 >100 1024 
0.002 0.000 4.096 0.659 >100 2048 
0.003 0.000 12.288 0.659 >100 4096 
 
Table 7: Assessment of the LSR II limit of detection for TNF-α+CD4+. Whole blood from 
an adult volunteer was left unstimulated or stimulated with BCG for 12 hours. Brefeldin-A was 
added in the last 5 hours to capture intracellular cytokines. The BCG sample was serially 
diluted with the unstimulated sample up to 4096 fold. The ICS assay was performed with the 
full 8-colour panel. For flow analysis, singlets cells were first selected and then lymphocytes. 
Thereafter, we selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. The 
frequencies of BCG-induced TNF-α+CD4+ was analyzed and corrected for background levels 
to give the observed frequencies. The observed frequencies in the undiluted sample was 
presumed to be the same as expected frequencies in the same sample. Subsequently, 
expected frequencies in the diluted samples were calculated by dividing the expected 
frequencies in the undiluted sample with the dilution fold. Then, the observed and expected 
frequencies were multiplied by the dilution fold and the percentage deviation between the two 
frequencies calculated. Deviations ≥ 30% were indicative of loss of senstivity to detect the 

















Observed  Expected  
Observed x 
dilution fold  
Expected x 




values (%) Dilution fold 
0.607  0.607  0.607  0.607  0.00 1 
0.257  0.304  0.514  0.607  15.32 2 
0.157  0.152  0.628  0.607  3.46 4 
0.080  0.076  0.640  0.607  5.44 8 
0.046  0.038  0.736  0.607  21.25 16 
0.033  0.019  1.056  0.607  73.97 32 
0.019  0.009  1.216  0.607  100.33 64 
0.008  0.005  1.024  0.607  68.70 128 
0.020  0.002  5.120  0.607  >100 256 
0.013  0.001  6.656  0.607  >100 512 
0.006  0.001  6.144  0.607  >100 1024 
0.014  0.000  28.672  0.607  >100 2048 
0.008  0.000  32.768  0.607  >100 4096 
 
Table 8: Assessment of the LSR II limit of detection for IL-2+CD4+.  Whole blood from an 
adult volunteer was left unstimulated or stimulated with BCG for 12 hours. Brefeldin-A was 
added in the last 5 hours to capture intracellular cytokines. The BCG sample was serially 
diluted with the unstimulated sample up to 4096 fold. The ICS assay was performed with the 
full 8-colour panel. For flow analysis, lymphocytes were selected followed by singlets cells. 
We thereafter selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. The 
frequencies of BCG-induced IL-2 +CD4+ was analyzed and corrected for background levels to 
give the observed frequencies. The observed frequencies in the undiluted sample was 
presumed to be the same as expected frequencies in the same sample. Subsequently, 
expected frequencies in the diluted samples were calculated by dividing the expected 
frequencies in the undiluted sample with the dilution fold. Then, the observed and expected 
frequencies were multiplied by the dilution fold and the percentage deviation between the two 
frequencies calculated. Deviations ≥ 30% were indicative of loss of senstivity to detect the 
















Observed  Expected  
Observed x 
dilution fold  
Expected x 




values (%) Dilution fold 
0.068  0.068  0.068  0.068  0.00 1 
0.024  0.034  0.048  0.068  29.41 2 
0.015  0.017  0.060  0.068  11.76 4 
0.007  0.009  0.056  0.068  17.65 8 
0.005  0.004  0.080  0.068  17.65 16 
0.0002  0.002  0.006 0.068  91.18 32 
0.004  0.001  0.256  0.068  276.47 64 
0.000  0.001  0.000  0.068  >100 128 
0.000  0.000  0.038  0.068  >100 256 
0.000  0.000  0.000  0.068  >100 512 
0.000  0.000  0.000  0.068  >100 1024 
0.001  0.000  1.618  0.068  98.53 2048 
0.000  0.000  0.000  0.068  >100 4096 
 
Table 9: Assessment of the LSR II limit of detection for IL-17+CD4+.  Whole blood from an 
adult volunteer was left unstimulated or stimulated with BCG for 12 hours. Brefeldin-A was 
added in the last 5 hours to capture intracellular cytokines. The BCG sample was serially 
diluted with the unstimulated sample up to 4096 fold. The ICS assay was performed with the 
full 8-colour panel. For flow analysis, lymphocytes were selected followed by singlets cells. 
We thereafter selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. The 
frequencies of BCG-induced IL-17+CD4+ was analyzed and corrected for background levels 
to give the observed frequencies. The observed frequencies in the undiluted sample was 
presumed to be the same as expected frequencies in the same sample. Subsequently, 
expected frequencies in the diluted samples were calculated by dividing the expected 
frequencies in the undiluted sample with the dilution fold. Then, the observed and expected 
frequencies were multiplied by the dilution fold and the percentage deviation between the two 
frequencies calculated. Deviations ≥ 30% were indicative of loss of senstivity to detect the 
















Figure 22: Flow cytometer’s limit of detecting BCG-induced cytokines Whole blood from 
an adult volunteer was left unstimulated or stimulated with BCG for 12 hours, and Brefeldin-A 
was added in the last 5 hours to capture intracellular cytokines. The BCG sample was serially 
diluted with the unstimulated sample up to 4096 fold. The ICS assay was performed with the 
full 8-colour panel. For flow analysis, lymphocytes were selected followed by singlets cells. 
We thereafter selected for CD3+ T cells from which we selected CD4+ and CD8+ T cells. The 
frequencies of BCG-induced IFN-γ+CD4+ (A), TNF-α+CD4+ (B), IL-2+CD4+ (C) and IL-
17+CD4+ (D) was analyzed and corrected for background levels to give the observed 
frequencies. The observed frequencies in the undiluted sample was presumed to be the 
same as expected frequencies in the same sample. Subsequently, expected frequencies in 
the diluted samples were calculated by dividing the expected frequencies in the undiluted 
sample with the dilution fold. Then, the observed and expected frequencies were multiplied 
by the dilutionfold and the frequencies plotted against the dilution fold. The observed and 
expected frequencies of BCG-induced CD4 T cell cytokines for corresponding dilution fold is 
detailed in Tables 2-5. The sensitivity of detecting the BCG-induced CD4+ T cell cytokines 
decreased with increased dilution. 
 
 
3.3.4 Fluorescence minus one (FMO) analysis 
Next, we aimed to assess the spectral overlap for the new 8-colour antibody-
fluorochrome combination selected. In PFC, larger panels may result in 
higher spectral overlap. When spectral overlap is not carefully corrected, 
there is a greater chance of measuring artifacts. Spectral overlap can be 
assessed and quantified by use of FMO controls. The FMO controls contain 
all the antibodies in the panel except the one being assessed (219). Absence 











channels. A high signal in an FMO control indicates high spectral overlap 
from other fluorochromes in the panel. To assess for the spectral overlap in 
our selected panel, fixed BCG-stimulated whole blood cells from an adult 
participant was split in to 9 aliquots. One of the 9 aliquots was stained with 
the full 8-color antibody-fluorochrome combination and the signal for each 
marker was quantified by measuring the frequencies of the stained markers. 
The other 8 aliquots were each stained with FMO controls and the spectral 
overlap detected in the control measured. The range for spectral overlap 
(shaded boxes) detected in our FMO controls was 0 to 0.06% (Table 10). We 
concluded that the spectral overlap detected for all 8 channels was low and 
would not compromise the reliability of the panel to evaluate for markers of 
interest.  
  
  Signal of the immunological marker detected (%) 
FMO CD3 CD4 CD8 
γδ  
TCR IL-2 IL-17 IFN-γ TNF-α 
Pac Blue 0.00 42.02 42.02 3.00 0.27 0.14 0.78 0.28 
Cy5.5PerCP 85.11 0.30 39.35 3.00 0.23 0.15 0.87 0.26 
Q Dots 605 82.67 41.19 0.00 3.00 0.25 0.15 0.91 0.28 
APC 83.00 40.17 37.83 0.05 0.24 0.16 0.81 0.26 
FITC 85.50 42.60 39.45 3.29 0.03 0.12 0.89 0.24 
PE 86.61 42.92 40.23 3.28 0.26 0.04 0.83 0.26 
Alexa Fluor 700 86.15 42.72 40.06 3.00 0.25 0.17 0.06 0.26 
Cy7PE 84.49 42.00 38.90 3.09 0.22 0.12 0.79 0.03 
Full Panel 82.00 40.88 37.63 3.00 0.26 0.12 0.87 0.30 
 
Table 10: Fluorescence minus one analysis of the 8-colour panel. Whole blood from an 
adult volunteer was stimulated with BCG, and staining performed with the antibodies defined 
in the table above. The spectral overlap was assessed by investigating the frequencies of 
cells with or without each single antibody-fluorochrome within the lymphocyte gate. In this 
analysis, the full 8-colour panel was run, as well as the 8 combinations of the panel minus a 
single antibody-fluorochrome (shaded boxes). The panel yielded minimal spectral overlap 













3.3.5 Intra-assay coefficient of variation (CV) analysis 
Next, we aimed to test if the results generated by our proposed 8-colour 
panel would be reproducible. Scientifically generated data should be 
reproducible for it to be considered valid. The CV, computed by dividing the 
mean by the standard deviation, can be used to assess for variability in a 
measurement. Although a CV of <8% is ideal for a clinical laboratory test, it is 
not unusual to find much higher CVs in immunological assays; a CV of up to 
30% may be considered acceptable (189). BCG-stimulated whole blood from 
an adult participant was split into six aliquots and each of the aliquots stained 
separately in one experiment using the final panel. Standardization of the 
stimulation and staining procedures ensured the intra-donor assay variability 
was independent of these procedures. The intra-assay CV ranged from 
1.77% for BCG-specific CD4+IFN-γ+ frequencies to 6.98% for BCG-specific 
CD4+IL-2+ frequencies (Table 11). We concluded that the proposed panel 













CD4+ Total cytokine expression (%)  CD8+ 
  IFN-γ  IL-2 IL-17 TNF-α  IFN-γ  
Sample 1 2.15 0.25 0.46 0.31 0.86 
Sample 2 2.23 0.30 0.44 0.35 0.84 
Sample 3 2.16 0.30 0.47 0.32 0.82 
Sample 4 2.21 0.31 0.45 0.32 0.90 
Sample 5 2.15 0.30 0.41 0.32 0.85 
Sample 6  2.23 0.27 0.46 0.31 0.92 
Median 2.19 0.30 0.46 0.32 0.85 
Minimum 2.15 0.25 0.41 0.31 0.82 
Maximum 2.23 0.31 0.47 0.36 0.92 
Mean 2.19 0.29 0.45 0.33 0.87 
SD 0.04 0.02 0.02 0.02 0.04 
CV (%) 1.77 6.98 4.50 4.75 4.25 
 
Table 11: Intra-assay coefficient of variation. Six whole blood samples derived from an 
adult volunteer were unstimulated or BCG stimulated, stained with the 8-colour panel, and 
acquired in a single experiment. The medians for the BCG-specific responses are reported, 
along with the minimums, maximums, and CVs for each cytokine. Background values were 
subtracted from the respective BCG-specific value. 
 
 
3.3.6 Gating strategy 
Our next step was to develop a flow data analysis strategy to address our 
research questions. The large amount of data generated by large PFC 
panels can be overwhelming. Thus, a gating strategy must be defined during 
the panel development process to facilitate a focused and objective driven 
analysis. Such a strategy is guided by the research questions developed 
prior to the selection of antigens for the panel. We used the intra-assay CV 
experiment to develop the analysis strategy. We selected for singlet cells 
first, followed by lymphocytes. We then gated on CD3+ T cells followed by 
CD3+γδTCR+ and CD3+γδTCR- cells. The CD4+ and CD8+ T cells were then 











IL-17 cytokine expression was then analyzed for γδTCR+, CD4+, CD8+ and 
γδTCR-CD4-CD8- T cells (Figure 23). This gating strategy was saved as an 
analysis template. Later, samples were stained, acquired and uploaded on to 
the analysis template for batch analysis. 
 
 
Figure 23: Gating strategy used for flow cytometry analysis. Doublets are excluded from 
the analysis by gating on forward-scatter (FSC)-height vs. FSC-area. The T cells are 
selected for by gating on CD3+ cells. The T cells are subsequently differentiated into CD3+ 
γδTCR- and CD3+ γδTCR+. The CD3+ γδTCR- population is subdivided into CD4+, CD8+ and 
CD4-CD8- T cells. The intracellular cytokine expression is analyzed as follows: (i) total IFN-γ, 
-IL-2, -IL-17 and -TNF−α expression is first assessed (4x4 outcomes), (ii) and then 
combinatorial cytokine profiles are assessed after Boolean analysis (4x 16 outcomes). 
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3.3.7 Pilot studies with samples from healthy adult volunteers 
Next, using our optimized 8-colour PFC panel, we aimed to assess whether 
the patterns of expression of BCG-induced cytokines were comparable to 
those previously reported in our laboratory. We first analyzed whole blood 
collected from six adult volunteers. Whole blood was left unstimulated or 
stimulated with BCG or SEB, followed by ICS analysis. We used the gating 
strategy described above to analyze the frequencies of T cells expressing 
cytokines. Data generated from flow analysis was exported to Microsoft 
Excel and thereafter to GraphPad Prism version 5.0a for analysis. 
Representative plots showing background, BCG- and SEB-induced IFN-γ, 
TNF-α, IL-2 and IL-17 frequencies in CD4+ (Figure 24), CD8+ (Figure 25), 
γδTCR+ (Figure 26) and γδTCR-CD4-CD8- T cells (Figure 27) are shown. 
The BCG-induced CD4+ and CD8+ T cell co-expression showed that the 
most dominant subset was single IFN-γ-producing cells (Figure 28A and B). 
For CD4+ T cells, other relevant subsets included polyfunctionals (IFN-
γ+TNF-α+IL-2+) and bifunctionals (IFN-γ+TNF-α+ and IFN-γ+IL-2+) (Figure 
28A). All background cytokine expression levels were minimal, allowing for 
sensitive detection of cytokines. We concluded that the patterns of BCG-
induced CD4+ and CD8+ T cell cytokines were comparable to those 














Figure 24: Intracellular cytokine expression in CD4+ T cells derived from whole blood 
of a representative BCG vaccinated adult. Whole blood was either left unstimulated (left 
panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 12 hours, and  
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for detection by 
flow cytometry. CD4+ T cells were stained intracellularly for IFN-γ and IL-17 (upper panel), 














Figure 25: Intracellular cytokine expression in CD8+ T cells derived from whole blood 
of a representative BCG vaccinated adult. Whole blood was either left unstimulated (left 
panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 12 hours, and 
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for detection by 
flow cytometry. CD8+ T cells were stained intracellularly for IFN-γ and IL-17 (upper panel), 














Figure 26: Intracellular cytokine expression in γδTCR+ cells derived from whole blood 
of a representative BCG vaccinated adult.  Whole blood was either left unstimulated (left 
panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 12 hours, and 
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines for detection by 
flow cytometry. γδT cells were stained intracellularly for IFN-γ and IL-17 (upper panel), TNF-















Figure 27: Intracellular cytokine expression in CD4-CD8-γδTCR- T cells derived from 
whole blood of a BCG vaccinated adult.  Whole blood was either left unstimulated (left 
panels), or was stimulated with BCG (middle panels) or SEB (right panels) for 12 hours, and 
Brefeldin-A was added in the last 5 hours to capture intracellular cytokines fore detection by 
flow cytometry. CD4-CD8-γδTCR- T cells were evaluated for IFN-γ and IL-17 (upper panel), 














Figure 28: T cell cytokine expression profiles defined after BCG stimulation of whole 
blood derived from adult volunteers vaccinated with BCG at birth. Whole blood 
samples derived from 6 adult volunteers were left unstimulated or stimulated with BCG for 
12 hours. Brefeldin-A was added in the last 5 hours to capture intracellular cytokines and 
subsequently stained with the 8-colour panel before acquisition on the flow cytometer. 
Frequencies of cytokine expressing (A) CD4+ T cell subsets and (B) CD8+ T cell subsets 













3.3.8 Pilot studies with samples from healthy 10-week old infants 
Our next step aimed to assess whether BCG-induced T cell cytokine 
patterns, measured with our optimized panel, would yield results comparable 
to those previously reported in a similar assay system with infant-derived 
whole blood samples. Whole blood from nine infants was left unstimulated or 
stimulated with BCG or SEB, followed by ICS analysis. We used the gating 
strategy described above to analyze the frequencies of T cells expressing 
cytokines. Data generated from flow analysis was exported to Microsoft 
Excel and thereafter to GraphPad Prism version 5.0a for analysis. 
Representative plots showing background, BCG and SEB-induced IFN-γ, 
TNF-α, IL-2 and IL-17 frequencies in CD4+ (Figure 29), CD8+ (Figure 30), 
γδTCR+ (Figure 31) and γδTCR-CD4-CD8- T cells (Figure 32) are shown. 
The BCG-induced CD4+ and CD8+ T cell co-expression showed that the 
most dominant subset was single IFN-γ+ producers (Figure 33A and B). For 
CD4+ T cells, the other relevant subsets included polyfunctionals (IFN-γ+TNF-
α+IL-2+) and bifunctionals (IFN-γ+TNF-α+ and IFN-γ+IL-2+) (Figure 33A). The 
cytokine expression patterns observed in infants for CD4+ and CD8+ T cells 
were similar to those observed in adults. Infants showed lower BCG-induced 
T cell cytokine frequencies than adults. All background cytokine expression 
levels were minimal, allowing for sensitive detection of cytokines. We 
concluded that the patterns of BCG-induced CD4+ and CD8+ T cell cytokines 














Figure 29: Intracellular cytokine expression in CD4+ T cells derived from whole blood 
of a representative 10-week old infant, BCG vaccinated at birth. Whole blood was 
either left unstimulated (left panels), or was stimulated with BCG (middle panels) or SEB 
(right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to capture intracellular 
cytokines for detection by flow cytometry. CD4+ T cells were stained intracellularly for IFN-γ 














Figure 30: Intracellular cytokine expression in CD8+ T cells derived from whole blood 
of a representative 10-week old infant, BCG vaccinated at birth. Whole blood was 
either left unstimulated (left panels), or was stimulated with BCG (middle panels) or SEB 
(right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to capture intracellular 
cytokines for detection by flow cytometry. CD8+ T cells were stained intracellularly for IFN-γ 














Figure 31: Intracellular cytokine expression in γδTCR+ T cells derived from whole 
blood of a representative 10-week old infant, BCG vaccinated at birth. Whole blood 
was either left unstimulated (left panels), or was stimulated with BCG (middle panels) or 
SEB (right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to capture 
intracellular cytokines for detection by flow cytometry. γδTCR+ T cells were stained 
intracellularly for IFN-γ and IL-17 (upper panel), TNF-α and IL-2 (lower panel). Cytokine 
















Figure 32: Intracellular cytokine expression in CD4-CD8-γδTCR- T cells derived from 
whole blood of a representative 10-week old infant, BCG vaccinated at birth. Whole 
blood was either left unstimulated (left panels), or was stimulated with BCG (middle panels) 
or SEB (right panels) for 12 hours. Brefeldin-A was added in the last 5 hours to capture 
intracellular cytokines for detection by flow cytometry. CD4-CD8-γδTCR- T cells were 















Figure 33: T cell cytokine expression profiles defined after BCG stimulation of whole 
blood derived from 10-week old infants vaccinated with BCG at birth. Whole blood 
from 9 infants were left unstimulated or stimulated with BCG, and subsequently stained with 
the optimized 8-colour panel before acquisition. Frequencies of cytokine expressing CD4+ T 
cell subsets (A) and CD8+ T cell subsets (B) are shown. The lines shown in the graph 














3.3.9 Enumeration of T cell events in whole blood from healthy 10-week 
old infants 
Our next step was to estimate the number of CD4+, CD8+, γδTCR+ and 
CD3+CD4-CD8-γδTCR- T cells from one milliliter of stimulated and fixed whole 
blood cells collected from a 10-week old infant. Adequate cell numbers are 
critical for reliable PFC analysis. Therefore it was important to establish 
whether we had sufficient cells for analysis. We used data generated from 
our nine infants’ pilot studies. The median number of cells for CD4+, CD8+, 




maximum) number of cells 
CD4+ 157,601 (31,815 - 597,000) 
CD8+ 56,690 (4,743 - 242,118) 
γδTCR+ 9,972 (1,509 - 27,721) 
CD3+CD4-CD8-γδTCR- 6,127 (2,001- 48,789) 
Table 12. Expected cell yields per milliliter of 10-week old infant blood. For the proposed 
studies, infant whole blood was cryopreserved in aliquots of 0.5mL for the unstimulated 
samples (negative controls), 1mL for the BCG stimulated samples, and 0.5mL for the SEB 
samples (positive controls). This table shows the average yields of lymphocytes calculated 




3.3.10 Assessment of minimum T cell numbers required for reliable 
analysis of samples from healthy 10-week old infants 
Finally, we aimed to determine the minimum number of cells that should be 
acquired to allow for reliable analysis of BCG-induced T cell cytokine 
expression in cryopreserved infant blood samples. In flow cytometry, 
collection of few cellular events increases the error rate of the results. We 
utilized an algorithm developed by Dr Holden Maecker 
(http://maeckerlab.typepad.com/maeckerlab_weblog/maeckerlab_protocols_
and_tools/index.html accessed on 16/10/2007). The algorithm factors in the 











levels, to determine the minimum number of events required for reliable 
analysis. We used the data generated from the nine infants in our pilot 
experiments, which revealed that approximately, 120,000 CD4+ T cells are 
required to obtain statistically significant results over background for all 
cytokines. This cell count was based on BCG-induced IL-17, which was least 
expressed of all the cytokines measured. For CD8+ T cells, we only 
established the minimum event count (28,649) for the IFN-γ+ subset, which 
was demonstrated to be the most dominant subset (Table 13). We 
concluded that we had sufficient cells in the cryopreserved infant samples for 
our analysis. Nevertheless, we planned to acquire the maximum number of 
cells in our studies. 
 
      CD4+   CD8+ 
Cytokine Expression IL-2+ IL-17+ TNF+ IFN-γ+ IFN-γ+ 
Background (%) 0.009 0.011 0.002 0.015 0.030 
BCG response (%) 0.073 0.028 0.050 0.191 0.090 
Minimum number of 
cells required 17,210 116,033 19,405 5,713 28,649 
 
Table 13. Power calculation for event acquisition. The median levels for backgrounds 
and BCG responses for each cytokine were calculated from a whole blood experiment 
performed on 9 infants.  
(http://maeckerlab.typepad.com/maeckerlab_weblog/maeckerlab_protocols_and_tools/index




In this chapter, we report the successful optimization of an 8-colour PFC 
panel. We used the optimized panel to measure the complex BCG-specific T 
cell cytokine pattern in adult and infant stimulated whole blood cells. We 
established that cryopreserved samples, collected for the study would yield 
sufficient cells to allow for a reliable analysis of BCG-specific T cell subsets. 
 
An optimal PFC panel must be preceded by clearly defined research 
questions, from which a list of candidate markers is developed. Our 











and IL-22) were selected based on the roles they are presumed to play in 
anti-Mtb host immunity. Subsequent exclusion of candidate markers was 
conducted after careful evaluation, and the following parameters were 
considered for selection of the panel: (i) the relevance of markers to address 
the research questions was determined through extensive literature reviews. 
(ii) the expression levels of the selected markers were assessed using the 
well-defined assay system. (iii) the capacity of the flow cytometer to measure 
multiple parameters was assessed. (iv) the quality and availability of 
antibody-fluorochrome combinations was carefully considered. (v) the 
availability of PFC panels already optimized and available in our laboratory. 
All these parameters were considered during the successful development of 
the panel. 
 
Optimal PMT settings must be established prior to assessing the 
performance of the panel. Suboptimal voltages may result in poor 
compensation between the different channels, and thereby compromise the 
outcome. The FMO for our optimized 8-colour PFC panel revealed minimal 
spectral “spill over” into any of the channels utilized. This finding, in addition 
to the low intra-assay CVs (2-7%) for the panel indicates the reliability of the 
results generated. 
 
We found our cytometer could reliably measure the BCG-induced T cell 
cytokines IFN-γ and IL-2, although the limit of detection for these cytokines 
were not as low as those of TNF-α and IL-17. We suspect this minor 
difference in detection limit may be due to the dim fluorochromes conjugated 
to IFN-γ and IL-2 cytokines. Staining index, a measure of the brightness of a 
fluorochrome, may vary with antibody-fluorochrome combinations (195) and 
possibly affect the limit of detection. Nevertheless, in our assay system, 
BCG-induced IFN-γ, and IL-2 are highly expressed cytokines. Hence, 
staining of these cytokines with fluorochromes of lower brightness index 













When optimizing panels for application in paediatric settings where blood 
volumes are limited, we emphasize the importance of using adult blood 
samples during the preliminary optimization steps. Adult blood samples are 
generally easier to obtain and larger volumes are available for 
troubleshooting. Nevertheless, before the analysis of infant samples, the 
panels optimized using adult samples must be tested with infant samples that 
closely resemble the actual study samples. We followed this process to 
generate results from whole blood derived from 9 infants that had been 
stimulated, processed and cryopreserved for a long period of time. 
Importantly, our results from the infant samples was comparable in 
magnitude and patterns to those reported by Soares et al. (130). 
 
Our data, and previous data from our lab, show that the detectable specific 
response in fixed cells from BCG stimulated whole blood is higher when 
using adult, compared with infant samples. This may be, in part, because 
infants have higher numbers of absolute lymphocytes count compared with 
adults (220), which can reduce the frequencies of the specific cells in infants. 
Also, it could be because infants have lower frequencies of memory 
lymphocytes than adults (220). Our approach did not include an assessment 
of absolute cell counts, nor memory markers. We therefore could not correct 
for these variables when comparing the detectable specific response in infant 
and adult samples. 
 
The challenges of conducting large TB immune correlates of risk studies in 
pediatric settings are multiple: (i) limited blood volumes are available, (ii) 
standardization of assay procedures, (iii) prolonged cryopreservation of 
samples, (iv) optimization of cytometry panels, and (v) development of 
optimal data analysis procedures. In this chapter, we show an iterative 
process for successfully overcoming these challenges and for generating 
reliable results. Importantly, from this optimization process, QDot 605-
conjugated antibody was introduced as a useful and reliable reagent in our 
laboratory, and a 6-colour flow panel was standardised that remains a core 












The importance of optimization in the development of flow cytometry panels 
is well recognized (195). Not only does this process ensure that reliable 
results are generated, but also yields a solid foundation for future studies. 
We utilized the panel described here in (Chapter four) and a modified version 
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Chapter 4: Specific T cell Frequency and Cytokine Expression Profile 
Do Not Correlate with Risk of Developing Tuberculosis, Following BCG 
Vaccination of Newborns 
 
Authors: Benjamin M. N. Kagina, Brian Abel, Thomas J. Scriba, Elizabeth 
J. Hughes, Alana Keyser, Andreia Soares, Hoyam Gamieldien, Mzwandile 
Sidibana, Mark Hatherill, Sebastian Gelderbloem, Hassan Mahomed, 
Anthony Hawkridge, Gregory Hussey, Gilla Kaplan, Willem A. Hanekom, and 
other members of SATVI 
 
Studies reported in this chapter were published in the American 
Journal of Respiratory and Critical Care Medicine (Am J Respir Crit 
Care Med. 2010 Oct 15;182(8):1073-9. Epub 2010 Jun 17). Additional 
results that were not published are included. 
 
4.1 Abstract 
The development of more effective TB vaccines is considered a key 
intervention in the control of global TB pandemic. However, the lack of known 
immune correlates of protection against TB is hampering development and 
testing of new vaccines against the disease. Immunogenicity of new TB 
vaccines is commonly assessed by measuring the frequency and cytokine 
expression profile of T cells. We tested whether this outcome correlates with 
risk of developing childhood TB disease, following newborn vaccination with 
BCG. 
 
Whole blood from 10-week old infants, routinely vaccinated with BCG at 
birth, was incubated with BCG for 12 hours, followed by cryopreservation for 
intracellular cytokine analysis. Infants were followed for 2 years to identify 
those who developed culture-positive TB – these infants were regarded as 
TB cases. Infants who did not develop TB disease despite exposure to TB in 
the household, and another group of randomly selected infants who were 
never evaluated for TB, were also identified – these groups were regarded as 











specific expression of IFN-γ, TNF-α, IL-2, and IL-17 in CD4, CD8, and γδ was 
measured. 
 
5,662 infants were enrolled; 29 cases and 2 groups of 55 control infants were 
identified. There was no difference in frequencies of BCG-specific CD4, CD8 
and γδ T cells between the 3 groups of infants. Although BCG induced 
complex patterns of intracellular cytokine expression, there were no 
differences between cases and control infants.  
 
The frequency and cytokine profile of mycobacteria-specific T cells did not 
correlate with risk of developing childhood TB. We propose that critical 
components of immunity against M.tb, such as CD4 T cell IFN-γ production, 




TB is a disease of global public health concern. In 2008, the WHO reported 
that TB disease kills 1.7 million people worldwide each year (128). The 
current TB vaccine, BCG, affords ~80% protection against severe forms of 
childhood TB (221, 222). However, BCG’s protection against pulmonary TB, 
particularly in adults, is highly variable and mostly poor (50). Adults with lung 
TB spread the disease; new, better TB vaccines that target pulmonary 
disease are therefore needed urgently. 
 
Our knowledge of immune correlates of protection against TB remains 
incomplete. Consequently, assessment of immunogenicity of TB vaccines 
may at best be a measure of vaccine take. Current evaluations of vaccine 
take focuses on immunity essential for protection against TB. For example, 
experimental and clinical evidence support a critical role for CD4 T cells, 
particularly IFN-γ production by these cells in protection against TB (223, 
224). IFN-γ production is therefore the most commonly measured when 
determining TB vaccine take. Since important roles for other type 1 











(227-229), in protection against TB have also been described, all these 
markers are commonly measured together, using PFC after short-term 
stimulation of whole blood or PBMC (105, 106, 230-233). Experimental 
animal studies assessing the efficacy of novel TB vaccines have reported an 
association between presence of mycobacteria-specific polyfunctional T cells 
that co-express IFN-γ, TNF-α and IL-2 at the site of the infection, and 
protection against TB (234). These findings have stimulated much interest in 
evaluating this subset of T cells in clinical trials. 
 
The study in this chapter aimed to assess whether these markers correlate 
with risk of developing childhood TB, following newborn vaccination with 
BCG. We complemented this assessment by also determining whether 
expression of IL-17 correlates with risk of developing childhood TB disease. 
Memory Th17 cells are present in peripheral blood of persons exposed to 
mycobacteria (212); experimental evidence supports a role for these cells to 
induce chemokine release in the lung resulting in Th1 cell recruitment (214). 
Furthermore, the magnitude of IL-17 response has been shown to correlate 
with the clinical outcome of M.tb infection (114). We also wished to determine 
whether γδ T cell activation correlates with a reduced risk of TB disease. This 
was based on potent mycobacteria-specific activation of γδ T cells in 7 
month-old infants who had received BCG vaccine at birth (235), and on 
experimental evidence that suggests an important role in protection against 
TB, possibly by activating APC to prime Th1 responses (200).  
 
4.3 Materials and methods 
4.3.1 Participant enrollment  
We enrolled participants at the SATVI field site in the Worcester area, near 
Cape Town, South Africa. This area has one of the highest TB incidence 
rates in the world, documented to be in excess of 1,000/100,000/year in 
children <2 years of age (5). The study was nested within a randomized 
controlled trial (RCT) (101), which aimed to determine whether intradermal or 
percutaneous delivery of Japanese BCG at birth resulted in equivalent 











age: mother known to be HIV-infected, BCG not received by infant within 24 
hours of birth, significant perinatal complications in the infant, any acute or 
chronic disease in the infant at the time of enrollment, clinically apparent 
anemia in the infant, and household contact with any person with TB 
disease, or any person who was coughing. The study was conducted 
according to the US Department of Health and Human Services and Good 
Clinical Practice guidelines. This included protocol approval by the University 
of Cape Town Research Ethics Committee and written informed consent 
from the parent or legal guardian. 
 
4.3.2 Blood collection, stimulation and cryopreservation 
At 10 weeks of age, heparinized blood was collected from all infants. 1mL 
was immediately incubated with BCG (SSI strain, 1.2 x 106 organisms/mL), 
as previously described (178). Medium alone served as negative control, 
while SEB (Sigma-Aldrich, 10µg/mL) was used as positive control. To all 
conditions the co-stimulatory antibodies anti-CD28 and anti-CD49d (BD 
Biosciences, 1µg/mL each) were added, as this results in enhancement of 
specific responses (178). Blood was incubated for 7 hours at 37oC. Brefeldin-
A was then added, followed by incubation for an additional 5 hours. Cells 
were then harvested, fixed and cryopreserved as previously described (178). 
 
4.3.3 Participant follow up and evaluation 
Participants were followed for 2 years. Community-wide passive surveillance 
systems identified patients with TB disease and children with symptoms 
suggestive of TB disease, or from households where an adult had TB 
disease (101). Children who fell into the latter 2 categories were followed up 
actively; among these, participants who never developed TB over the 2 year 
follow up period were classified as household controls, while participants who 
developed TB disease over this period were classified as TB cases. 
Community controls were randomly selected from the passive surveillance 
arm and were never evaluated for TB. The parent study (101), reports the 
detailed criteria employed to detect all cases of TB disease among 











compatible with TB disease, or who had contact with an adult with TB 
disease, were admitted to a dedicated research ward for clinical examination, 
chest radiography, tuberculin skin testing, two early morning gastric 
aspirations and two sputum inductions for M.tb smear and culture (101). All 
infants admitted to the research ward were also tested for HIV infection: a 
positive antibody test resulted in exclusion. 
 
4.3.4 Intracellular cytokine staining and multi-parameter flow cytometry 
Cryopreserved cells from the cases and control groups (see data analysis 
below) were thawed, washed and permeabilised using Perm wash solution 
(BD Biosciences). Cells were then incubated at 4oC for 1 hour with 
fluorescence-conjugated antibodies directed against surface antigens and 
intracellular cytokines. The following antibodies were used: anti-CD3 Pac 
Blue (clone UCHT1), anti-CD8 Cy5.5PerCP (SK-1), anti-γδTCR APC (B1), 
anti-TNF-α Cy7PE (Mab11), anti-IFN-γ Alexa 700 (B27), anti-IL-2 FITC 
(5344.111, all from BD Biosciences), anti-CD4 QDot605 (S3.5, Invitrogen), 
and anti-IL-17 PE (eBio64CAP17, eBioscience). Cells were acquired on a 
LSRII flow cytometer (BD Biosciences) configured with 3 lasers and 10 
detectors, using FACS Diva 6.1 software. Optimal photomultiplier tube (PMT) 
settings were established for this study prior to sample analysis. Cytometer 
Setting and Tracking (CST) beads (BD Biosciences) were used to record the 
target MFI values for the baseline settings, and these calibrations were 
performed each day prior to sample acquisition. Compensation settings were 
set using anti-mouse kappa-beads (BD Biosciences), labelled with the 
respective fluorochrome-conjugated antibodies. Flowjo version 8.8.4 
(Treestar) was used to compensate and to analyze the flow cytometric data. 
Boolean gating was applied to generate combinations of cytokine expressing 
CD4 and CD8 T cell subsets. 
 
4.3.5 Data analysis 
Flow cytometric analysis was compared between the 3 groups of infants: (1) 
those who ultimately developed culture-confirmed TB disease; regarded as 











exposure to an adult with TB disease, but found not to have TB; regarded as 
household controls, (3) a third, randomly selected group, who had no known 
exposure to an adult with TB disease, or symptoms compatible with TB 
disease, and were therefore never evaluated for TB; this was the second 
group regarded as community controls. Twenty TB cases were excluded 
from the analysis due to insufficient sample volume for analysis. The 
microbiological, clinical and radiological features of the excluded TB cases 
were comparable to those of the included TB cases. 
 
For flow cytometric analysis of cytokine-expressing cells, frequencies of 
cytokine expression from the negative control, i.e., blood incubated with co-
stimulatory antibodies alone, were subtracted from the BCG-specific 
responses. Participants were excluded from the analysis for any of the 
following reasons: (1) a positive control (SEB) CD4 T cell response less than 
the median plus 3 median average deviations (MADs) of the CD4 T cell 
response in the negative control, (2) CD4 T cell frequencies in the negative 
control and in the BCG sample in a similar range, suggesting possible 
contamination of the negative control, (3) number of CD3 T cell events 
counted < 75,000. In infants, BCG-specific responses are predominantly 
present in the CD4 T cell subset. As such, all exclusions were based on the 
responses in this subset. 
 
For the analysis of median fluorescence intensities (MFI) of the BCG-
stimulated samples, further exclusions occurred if results from participants 
did not meet any of the following conditions: (1) ratio of BCG to unstimulated 
frequencies > 2, (2) frequencies of BCG-specific cells > 0.01%, (3) number of 
positive events in the BCG-stimulated sample > 20. The Kruskal-Wallis test 
was used to assess differences between the 3 groups, and when differences 
had a p value <0.05, a Mann-Whitney U test was used to assess differences 













4.4.1 Study participants 
A total of 5,724 infants routinely vaccinated with BCG at birth, were randomly 
enrolled from the parent cohort of 11,680 infants (101). Identification of the 3 
infant groups, with clinical exclusions, is shown in Figure 34. All the three 
infant groups had comparable proportions of infants who received either 
intradermal or percutaneous BCG at birth. 
 
 
Figure 34: Study participants. Recruitment and enrollment of participants into the study. 
 
 
4.4.2 Gating strategy  
To analyse for specific cells of interest, we modified the strategy developed 















Figure 35: Gating strategy. Flow cytometric analysis of BCG-induced T cell cytokine 
production. Whole blood was incubated with BCG for 12 h. Representative dotplots from a 
single participant are shown. (A) Gating strategy used to identify CD4, CD8, and γδ T cells. 
From left to right, leukocytes from whole blood were acquired and cell doublets excluded 
using forward scatter-area versus forward scatter-height parameters. T cells were identified 
by assessing CD3 expression against IFN-γ expression, which enables inclusion of any T 
cells that may have down-regulated CD3 expression upon activation. Subsequently, CD3+ T 
cells were differentiated into conventional T cells, which did not express γδTCR, and γδ T 
cells, by assessing γδ expression against CD8 expression. Finally, the conventional T cell 
population was divided into CD4+ and CD8+ T cells. (B) Representative dot plots of cytokine 












4.4.3 Participants excluded from analysis based on quality control 
criteria 
To ensure only reliable data analysis was reported, we developed an internal 
quality control system that would exlude participants whose data fell below 
the quality control criteria as described in the data analysis section. The 
Tables 14A to I show a summary of the number of participants excluded. 
 
Table 14A: Exclusion of participants from analysis based on flow 
cytometry data: Frequency of cytokine-producing cells 








SEB responses < median + 3 
MAD of the negative control 
0 1 1 
Frequency of negative control 
similar to that of BCG sample  
0 0 3 
CD3 T cell counts <75,000  0 2 0 
 
Table 14B: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IL-2 only 








Ratio of BCG to unstimulated 
frequency <2 
0 6 5 
BCG-specific frequency < 
0.01% 
0 0 0 
BCG event counts <20 0 0 1 
 
 Table 14C: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IFN-γ  only 








Ratio of BCG to unstimulated 
frequency <2 
2 3 5 
BCG-specific frequency < 
0.01% 
0 0 3 
BCG event counts <20 0 0 0 












Table 14D: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing TNF-α  only 








Ratio of BCG to unstimulated 
frequency <2 
11 18 22 
BCG-specific frequency < 0.01% 0 0 0 
BCG event counts <20 1 0 2 
 
Table 14E: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IL-17 only 








Ratio of BCG to unstimulated 
frequency <2 
6 15 21 
BCG-specific frequency < 
0.01% 
0 0 0 
BCG event counts <20 0 0 1 
 
Table 14F: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IFN-γ  and IL-2 together 








Ratio of BCG to unstimulated 
frequency <2 
1 0 0 
BCG-specific frequency < 
0.01% 
0 0 0 
BCG event counts <20 1 4 3 
 
Table 14G: Exclusion of participants from analysis based on flow 
cytometry data:  MFI in cells expressing IL-2 and TNF-α  together 








Ratio of BCG to unstimulated 
frequency <2 
1 1 0 
BCG-specific frequency < 
0.01% 
0 0 0 












Table 14H: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IFN-γ  and TNF-α  together 








Ratio of BCG to unstimulated 
frequency <2 
1 2 2 
BCG-specific frequency < 
0.01% 
0 0 0 
BCG event counts <20 1 3 3 
 
Table 14I: Exclusion of participants from analysis based on flow 
cytometry data: MFI in cells expressing IFN-γ , IL-2 and TNF-α together 








Ratio of BCG to unstimulated 
frequency <2 
1 0 0 
BCG-specific frequency < 
0.01% 
0 0 0 
BCG event counts <20 0 3 3 
 
 
4.4.4 Frequency and cytokine profile of BCG-specific CD4 T cells 
To assess whether BCG-specific T cells was associated with the risk of 
childhood TB disease development, following BCG vaccination at birth, we 
used a intracellular cytokine assay to evaluate the frequency and cytokine 
profiles of BCG-specific T cells: A median of 409,077 (154,687 - 802,636) 
CD3 T cells were evaluated. Results from 7 participants were excluded from 
analysis, because the inclusion criteria for analysis were not met (Table 
14A). we compared CD4 T cell expression of IFN-γ, TNF-α, IL-2, and Il-17 in 
the cases and the two control groups. 
 
Frequencies of total cytokine-expressing BCG-specific CD4 T cells, 
expressing any of the 4 cytokines, were not different in the 3 groups (Figure 
36A). In addition, no differences were observed when frequencies of BCG-
specific Th1 CD4 T cells, either expressing IFN-γ, or TNF-α, or IL-2, were 











(Figure 36A). In all three groups, IFN-γ+−expressing CD4 T cells comprised 
the dominant subset (Figure 36A), whilst IL-17+-expressing CD4 T cells was 
the least frequent (Figure 36A). We also compared the cytokine co-
expression pattern of BCG-specific CD4 T cells. Polyfunctional CD4 T cells, 
co-expressing IFN-γ, TNF-α and IL-2, and single IFN-γ+-expressing CD4 T 
cells were the dominant subsets (Figure 36B). No differences were observed 
in the frequencies of any BCG-specific CD4 T cells subset within the three 
groups including polyfunctional CD4 T cells and single IFN-γ+ expressing 
CD4 T cells. We conclude that using this assay system; both quantitative and 
qualitative BCG-specific CD4 T cell responses are not associated with 
reduced risk of TB disease development in infants, following BCG 













Figure 36: Frequency and cytokine expression profile of BCG-specific CD4 T cells  
(A) Frequencies of total, IL-2, IFN-γ, TNF-α, and IL-17 cytokine expressing CD4 T cells, as 
detected by an intracellular cytokine assay, following incubation of whole blood with BCG. 
Total cytokine frequencies incorporate all cytokine positive CD4 T cells. Results are shown 
in box and whiskers plots. Whiskers represent the maximum and minimum value; the box 
represents the interquartile range, while the line in the box represents the median. One 
participant had a very high total and IFN-g CD4 T cell response (4.010% and 3.797%, 
respectively), and these values are shown individually as dots on the graph. (B) Frequencies 
of distinct subsets of specific CD4 T cells, based on combinations of cytokine expression. 
After selecting CD4 T cells, boolean gating was utilized to generate 15 distinct cytokine 
expressing subsets. The Kruskal-Wallis test was used to assess differences between the 




4.4.5 Frequency and cytokine profile of BCG-specific CD8 T cells 
Since CD8 T cells have been shown to be important in protection against TB, 
we investigated whether frequencies of BCG-specific CD8 T cell responses 
correlated with risk of developing childhood TB. We found no differences in 
the frequencies of total cytokine-expressing BCG-specific CD8 T cells within 
the three groups (Figure 37A). The dominant subset comprised total IFN-γ-











were observed within the three groups. CD8 T cells expressing TNF-α or IL-2 
or IL-17 were very infrequent in many infants (Figure 37A). Again, no 
differences in these T cell subsets were observed within the TB cases and 
control groups (Figure 37A). When the CD8 T cell subsets defined by 
cytokine co-expression patterns were evaluated, no differences were 
observed for any of the subset (Figure 37B). The dominant co-expression 
pattern for CD8 T cell subsets was single IFN-γ but when this response was 
compared within groups, there was no statistical difference (Figure 37B). 
 
 
Figure 37: Frequency and cytokine expression profile of BCG-specific CD8 T cells.  
(A) Frequencies of total, IL-2, IFN-γ, TNF-α, and IL-17 cytokine expressing CD8 T cells, as 
detected by an intracellular cytokine assay, following incubation of whole blood with BCG. 
Total cytokine frequencies incorporate all cytokine positive CD8 T cells One participant had 
a very high total and IFN-γ CD4 T cell response (6.198% and 6.157%, respectively), and 
these values are shown individually as dots on the graph. (B) Frequencies of distinct subsets 
of specific CD8 T cells, based on combinations of cytokine expression. After selecting CD8 T 
cells, boolean gating was utilized to generate 15 distinct cytokine expressing subsets. One 
participant had a very high IL-2 CD4 T cell response (0.199%), and this value is shown 
individually as a dot on the graph. Results are shown in box and whiskers plots. Whiskers 
represent the maximum and minimum value; the box represents the interquartile range, 
while the line in the box represents the median. The Kruskal-Wallis test was used to assess 
differences between the groups of infants. None of the parameters assessed were different 











4.4.6 BCG-induced γδ T cell response 
We assessed whether γδ T cell responses may correlate with risk of TB 
disease following BCG-vaccination of infants at birth. We analysed 
expression of IFN-γ, TNF-α, IL-2 and IL-17 by γδ T cells upon BCG 
stimulation of whole blood from infants in the three groups. In all infants, the 
γδ T cells induced by BCG stimulation almost exclusively produced IFN-γ; as 
seen for conventional T cell responses, no significant differences were 
observed within the infant groups (Figure 38). A very small γδ T cell subset 
expressed TNF-α, but again, no statistical differences in TNF-α producing γδ 
T cells between the groups were observed. IL-2 and IL-17 expression were 
negligible in γδ T cells (Figure 38). 
 
 
Figure 38: BCG-induced γδ  T cell responses. Frequencies of γδ T cells expressing 
cytokines, following incubation of whole blood with BCG. The Kruskal-Wallis test was used 
to assess differences between the groups of infants. Results are shown in box and whiskers 
plots.  None of the parameters assessed were different between groups (all: p>0.05). 
 
 
4.4.7 Comparable BCG-induced CD3- responses in the case and control 
groups 
We also observed intracellular IFN-γ+ expression by CD3- cells (non-T cell) 
upon BCG stimulation, and compared the frequencies of these cytokine-











statistical differences in IFN-γ-expressing CD3- cells between the infant 





Figure 39: BCG-induced CD3- cell responses in infants from TB cases, community and 
household controls, following BCG vaccination at birth. Frequencies of total BCG-
induced CD3- cell responses detected by a short-term whole blood intracellular cytokine 
assay are shown. The horizontal lines represent the medians, the boxes represent the inter-
quartile ranges, and the whiskers indicate the minimum and maximum values. Results are 
shown in box and whiskers plots.  The Kruskal-Wallis test was used to test for the statistical 
differences in the frequencies of BCG-specific cells for different subsets. 
 
 
4.4.8 Median fluorescent intensity of cytokine expression in BCG-
specific T cells 
Median fluorescence intensity of cytokine expression has been suggested as 
a useful readout of the “quality” of a T cell response, because the intensity of 
cytokine expression appears to be highest in polyfunctional T cells (237). We 
therefore compared the MFI of cytokine expression of BCG-induced CD4, 
CD8 and γδ T cells between the 3 groups. Participants were excluded from 
analysis if the above-mentioned inclusion criteria were not fulfilled for the flow 
cytometric data (Tables 14B-I). We found no differences in any of the MFI 
values evaluated between the TB cases and the control groups (CD4 T cell 














Figure 40: Median fluorescence intensity of BCG-specific CD4 T cells  
CD4 T cells expressing cytokines were selected by boolean gating, after detection with an 
intracellular cytokine assay, following incubation of whole blood with BCG. The median 
fluorescence intensities (MFI) of individual cytokines were analyzed, in cells that produced: 
(A) IL-2 only, (B) IFN-γ only, (C) TNF-α only, (D) IL-17 only, (E) IFN-γ and IL-2 together, (F) 
IL-2 and TNF-α together, (G) IFN-γ and TNF-α together, (H) IFN-γ, IL-2 and TNF-α together. 
The Kruskal-Wallis test was used to assess differences between the groups of infants.  
Results are shown in box and whiskers plots.  None of the parameters assessed were 




We report that, following newborn BCG vaccination, the magnitude and 
profile of cytokine expression of BCG-specific CD4 and CD8 T cells did not 
show association with risk of childhood TB disease development. 
Importantly, there were no differences in polyfunctional BCG-specific CD4 T 
cells, which co-express IFN-γ, TNF-α and IL-2. We also confirm production of 
IFN-γ by γδ T cells and by CD3- cells when whole blood is stimulated with 
BCG; however, expression of this cytokine by these subsets was not 
associated with reduced risk of childhood TB. 
 
Multiple experimental studies have shown that the Th1 cytokines, IFN-γ and 
TNF-α, are required for immunity against M.tb infection and disease (210, 











studies that evaluated biomarkers of protection (239-241). For example, in a 
heterologous prime-boost strategy of BCG followed by adenovirus 
expressing Ad85A, Forbes et al. reported a correlation between magnitude of 
polyfunctional Ad85A-specific Th1 responses in the lungs after M.tb 
challenge and protection against disease (234). Transfer of ESAT-6-specific 
Th1 memory cells to recipient mice before M.tb challenge enhanced 
protection, suggesting that the quantity of antigen-specific T cells at the 
disease site is important (242). In contrast, multiple other experimental 
studies have shown that IFN-γ production at the disease site does not 
correlate with protection against TB; rather, expression of the cytokine may 
be a marker of the magnitude of the inflammatory response (243, 244). For 
example, Mittrucker et al. reported no correlation of BCG-induced T cell 
responses and protection in a mouse TB challenge model (243). 
Furthermore, in a clinical study, Sutherland et al. reported that TB diseased 
patients had a higher polyfunctional CD4+ T cell response after overnight 
stimulation of whole blood with ESAT-6 and PPD compared with healthy 
individuals with a positive tuberculin skin test (245). 
 
In our study, we did not measure IFN-γ at a disease site – this is not possible 
in healthy 10-week old infants – but in peripheral blood. We found no 
association between the frequency of BCG-specific Th1 cells and risk of 
childhood TB disease. We could not evaluate the correlates of protection 
because all infants in our study had received BCG vaccine. In a setting 
where TB is endemic, it would not be ethical to have an unvaccinated cohort. 
We propose that our results are important because this peripheral blood 
outcome is used to assess vaccine take in most clinical trials of new TB 
vaccines. The latter studies often focus on the quality of the CD4 T cell 
response, with the hypothesis that polyfunctionality, i.e., combined 
expression of IFN-γ, TNF-α and IL-2 by individual cells, is a marker of 
protective immunity. We showed no correlation between polyfunctional BCG-












In an experimental mouse model with Leishmania major infection, Darrah et 
al. reported that MFI of cytokine expression could be used as an additional 
measure of quality of the T cell response, as polyfunctional cells had the 
highest MFI of cytokine expression (237). In this study, we assessed the MFI 
of BCG-specific T cell cytokine expression and showed no association with 
risk of TB disease. 
 
We evaluated IL-17 expression in CD4 T cells based on evidence that this 
cytokine plays a protective role against TB (214). This is the first study to 
demonstrate induction of BCG-specific IL-17 cells in infants, following BCG 
vaccination at birth; however, frequencies of BCG-specific Th17 cells did not 
correlate with risk of childhood TB. 
 
We investigated CD8 T cell responses as possible correlates of risk based 
on the important role of this subset suggested by recent experimental and 
clinical studies (228, 229). For example, Chen et al. reported that depletion of 
CD8 T cells in BCG-vaccinated rhesus macaques led to a decrease in 
induced immunity upon subsequent challenge of the animals with M.tb (228). 
Furthermore, Bruns et al., showed that patients undergoing anti-TNF therapy 
had decreased antimicrobial activity against M.tb due to diminished numbers 
of antigen-specific effector memory CD8 T cells, with an associated 
increased incidence of TB disease (229). We observed no differences when 
comparing specific CD8 T cell responses between cases and control infants. 
  
We assessed γδ T cell responses based on a report that only γδ T cells 
expanded from PBMC of PPD positive donors incubated with BCG, and not 
γδ T cells expanded by phosphoantigen, were able to inhibit growth of M.tb in 
autologous macrophages (246). However, we found no association between 
the frequency of BCG-induced γδ T cells and reduced risk of childhood TB in 
our study. 
 
Our results strongly suggest that aspects of antigen-specific CD4 and CD8 T 











BCG as antigen in this whole blood assay, may not correlate with risk of 
childhood TB. It is likely that this type of immunity may not correlate with 
protection against TB either. For future similar studies, it would be ideal to 
include multiple time points for immunogenicity analysis. We propose time 
points 6, 10 and 14 weeks, 6, 9 and 12 months are rational to include. From 
unpublished data by Soares et al. in our laboratory, BCG-induced immune 
response is shown to peak at 6 weeks of age in infants. Time points 6, 10 
and 14 weeks of age would allow the investigator to evaluate effector 
responses. Time points 6, 9 and 12 months would allow the investigator to 
assess established memory T responses.  Therefore, we cannot exclude that 
these outcomes, measured at multiple time points after newborn BCG 
vaccination, or using different antigens or assay systems, might correlate 
with risk of childhood TB. 
 
An infant biomarker study of this size (n=5,662) has not been reported, to 
date; the magnitude of the project required that we limit our blood collection 
to one practical time point, prior to M.tb infection, and at an age before 
significant exposure to environmental mycobacteria. This was also the 
reason for selecting a single viable bacterial antigen that can be processed 
for recognition by a wide range of lymphocytes. 
 
The results generated from using BCG as an antigen are likely to be specific. 
In chapter five, we showed that responses using BCG in a whole blood assay 
are detectable at 10 weeks of age only in infants who have been vaccinated 
at birth, and not in unvaccinated infants (247). Regardless, individual 
mycobacterial antigens might yield different results. 
 
The T cell response to mycobacteria is complex (248), and involves cytotoxic 
activity (249, 250), for example, in addition to cytokine production. These 
additional aspects of T cell immunity might correlate with outcome, while 
routine vaccine take measurements focus on cytokine production, using an 
assay like ours. We propose additional approaches are useful. For example, 
in addition to assessing the frequencies of BCG-specific T cells, evaluation of 











useful. This approach may help to control or explain for the different number 
of total CD4+ and CD8+ T cells that are inherently present in a population, 
which is not possible to account for when the data is analysed as 
frequencies. Similarly, innate host responses may also be important. We 
propose that biomarkers of protection against TB may only be unraveled 
when multiple host factors are examined together in a system biology 
approach. Ongoing, complementary studies will address whether biomarkers 
of risk of childhood TB may be identified through other approaches. These 
include measuring soluble levels of cytokines, chemokines, and growth 
factors after 7 hours’ incubation of whole blood with BCG; the cytotoxic, 
proliferative, and cytokine expressing capacity of T cells following incubation 
of PBMC with BCG for 3-6 days; and gene expression profiles in PBMC 
incubated with BCG for 12 hours. 
 
One big caveat to assays that are hypothesis driven is a selection bias; we 
select immune parameters that we think are important. In the absence of in 
depth knowledge on immune parameters mediating protection against TB, 
such approaches have obvious limitations. Therefore, it is rational to prioritize 
unbiased approaches that generate high throughput data such as global 
transcriptome analysis.  
 
We observed potent BCG-specific IFN-γ production by CD3- cells in our study 
groups. IFN-γ production is a critical event in the immune response to M.tb. 
We speculate that the CD3- cells are NK cells (236), which have been shown 
to mediate killing of M.tb in human monocytes (251). In M.tb infection, NK 
cells have been shown to be the early producers of IFN-γ that may facilitate a 
cross talk between the innate and adaptive immune responses (251). Our 
results showed that the magnitude of IFN-γ production by CD3- cells was 
similar in all the three groups of infants and could not be associated with 
reduced risk of childhood TB. 
 
Overall, our results strongly suggest caution when interpreting T cell immune 











importantly, our results indicate that protective immunity against M.tb may be 
very complex, and suggests a need to look beyond the classical Th1 
immunity when assessing the efficacy of novel TB vaccines in clinical trials.  
 
4.6 Contributions  
B.M.N. Kagina designed the experiments, conducted the laboratory and data 
analysis, and wrote this chapter under the supervision of Prof. W.A. 
Hanekom, Dr. B. Abel, and other members of SATVI laboratory. Study 
design and sample collection was done by Prof. W.A Hanekom and other 











Chapter 5: Delaying BCG vaccination from birth to 10 weeks of age may 
result in an enhanced memory CD4 T cell response 
 
Authors: Benjamin M. N. Kagina, Brian Abel, Mark Bowmaker, Thomas J. 
Scriba, Sebastian Gelderbloem, Erica Smit, Mzwandile Erasmus, Nonhlanhla 
Nene, Gerhard Walzl, Gillian Black, Gregory D. Hussey, Anneke C. 
Hesseling, Willem A. Hanekom 
 
Studies reported in this chapter were published in the Vaccine journal, 
(Vaccine. 2009 Sep 4;27(40):5488-95. Epub 2009 Jul 17). The chapter 
contains additional information that was left out in the publication. 
 
5.1 Abstract 
In most tuberculosis (TB) endemic countries, BCG is usually given around 
birth to prevent severe TB in infants. The neonatal immune system is 
immature. Our hypothesis was that delaying BCG vaccination from birth to 10 
weeks of age would enhance the vaccine-induced immune response.  
In a randomized clinical trial, BCG was administered intradermally either at 
birth (n=25) or at 10 weeks of age (n=21). Ten weeks after vaccination, and 
at 1 year of age, vaccine-specific CD4 and CD8 T cell responses were 
measured with a whole blood intracellular cytokine assay. 
Infants who received delayed BCG vaccination demonstrated higher 
frequencies of BCG-specific CD4 T cells, particularly polyfunctional T cells 
co-expressing IFN-γ, TNF-α and IL-2, and most strikingly at 1 year of age. 
Delaying BCG vaccination from birth to 10 weeks of age enhances the 
quantitative and qualitative BCG-specific T cell response, when measured at 














Worldwide, more than 100 million children receive BCG each year (221). 
Studies have shown that neonatal BCG vaccination confers protection 
against severe forms of childhood TB, i.e. TB meningitis and miliary TB (221, 
222). The protection afforded by BCG vaccination against pulmonary TB, the 
most common form of TB, is variable and mostly poor (50). Several factors 
have been implicated in variable efficacy of BCG against TB. These factors 
include the BCG strain, BCG dose, prior exposure to environmental NTM, 
host genetic variations, M.tb strain, vaccination route and schedule (50, 252-
254).  
 
Our laboratory has previously studied the effect of BCG strain, vaccination 
route and host genetics on BCG-induced immunity. For example, a study by 
Hawkridge et al. reported that two different BCG strains and vaccination 
routes might not influence the immunogenicity and the efficacy levels in 
infants (101). In adults with history of BCG vaccination, a study by Shey et al. 
showed that SNP on TLR 6 could influence mycobacteria-specific responses 
after stimulation of whole blood with specific antigens for 20hrs (255). The 
South African BCG vaccination policy advocates for at birth or soon after 
birth vaccination schedules. The NTM exposure is unlikely to occur at birth or 
soon after birth; hence NTM may not influence BCG immunogenicity in South 
Africa. In this chapter, we chose to assess the effect of vaccination timing on 
the vaccine take immune responses. 
 
It has been shown that T cell mediated immunity is important against TB. The 
CD4 T cells that produce the Th1 cytokines: IFN-γ, TNF-α and IL-2 are 
thought to be critical for protection against TB (256, 257). This kind of Th1 
response is characteristic following BCG vaccination (130, 258). In areas 
where TB is highly prevalent, BCG vaccination is widely administered at or 
soon after birth because of the risk of early exposure to M.tb (124). Evidence 
exists that the Th1 response at birth is “immature”, for example, 
progressively increasing specific Th1 cell-mediated immunity has been 











respectively (259). We proposed that allowing maturation of the neonatal 
immune system to 10 weeks of age prior to BCG vaccination would enhance 
vaccination-induced T cell immunity. 
 
Administration of BCG vaccine soon after birth improves on the BCG 
vaccination coverage. Consequently, BCG vaccination coverage in South 
Africa is very high. For example, in 2005, BCG coverage in the Western 
Cape of South Africa was 99% (260). One of the caveats to the 10-week 
delay in BCG vaccination would be an increased chance of infants missing to 
get the vaccine altogether in their lifetime, which may reduce BCG 
vaccination coverage. This may result in increased incidence of disseminated 
TB (261). However, the 10-week delay falls within the schedule when the 
infants return to health facilities for other EPI vaccines (262). This could 
reduce the chance of infants missing to get the vaccine by this age. The risk 
of M.tb infection by 10 weeks of age is low as well as the risk of exposure to 
NTM, which are present in water, soil, and biofilms (263). BCG vaccination in 
HIV infected infants may cause BCGiosis (156). Neonatal HIV testing at birth 
is insensitive due to the persistence of passively transferred maternal anti-
HIV antibodies. Therefore, the 10-week delay in BCG vaccination may 
benefit newborns born to HIV infected mothers as their HIV infection could be 
accurately determined by this age, allowing for an informed decision on 
whether to administer the vaccine. The effects of optimizing vaccination 
timing could have important implications for ultimately improving protection 
against TB disease through BCG vaccination. 
 
Marchant et al. reported that varying the age of BCG vaccination did not 
affect BCG immunogenicity when assessing interferon gamma (IFN-γ) 
production by PBMC stimulated with mycobacterial antigens (258). Hussey et 
al. also reported that a delay in BCG vaccination from birth to 10 weeks of 
age did not influence IFN-γ secretion, proliferative responses, or cytotoxic 
potential of BCG-specific T cells, following incubation of PBMC with 
mycobacterial antigens (136). Since these results have emerged, we have 











the BCG-induced Th1 response. BCG vaccination in infants induces multiple 
Th1 subsets, defined by expression of different combinations of IFN-γ, TNF-α 
and IL-2 by specific cells (130). We wished to comprehensively address the 
effect of age on the magnitude and quality of Th1 immunity induced by BCG 
in infants. The quality (cells expressing multiple cytokines) of vaccine-specific 
immune responses is a key outcome in assessing immunogenicity. 
Evaluation of vaccine-specific cells expressing multiple cytokines has been 
shown to correlate with protection in different vaccination preventable 
disease models (264-266). 
 
5.3 Materials and methods 
5.3.1 Participant enrolment and follow-up 
Participants were enrolled between April 2006 and March 2008 in 
Khayelitsha, a suburb of Cape Town with an extraordinarily high TB 
incidence, reported to be 1,614 per 100,000 in the first quarter of 2008 (Case 
notification rate, City of Cape Town). 
 
This formed part of a larger study investigating clinical and immunological 
characteristics of HIV-exposed and unexposed infants. In brief, pregnant 
women were approached at a public antenatal clinic for enrolment of their 
infants. For the study reported here, infants who were born to HIV-infected 
women or women with unknown HIV status, exposed to active TB in the 
household, born prematurely (≤36 weeks gestational age) or had low birth 
weight (≤2.5kg), or who had significant perinatal complications were 
excluded. In addition, all infants with a positive IFN-γ response to ESAT-
6/CFP-10 at 10 weeks of age were excluded (see below for assay details). 
Infants were randomly assigned during antenatal recruitment to receive BCG 
(intradermal Danish strain 1331, Statens Serum Institute) on the first day of 
life (“birth vaccination”), or the identical BCG vaccination at 10 weeks of age 
(“delayed vaccination”). Infants were followed at 10 weeks, 20 weeks and at 
50 weeks of age. A window period of -2 to + 4 weeks around the week 10 
visit was allowed (e.g. 8 to 14 weeks). The time period for the 20-week visit 











Regulatory approval was obtained from the research ethics committees of 
Stellenbosch University and the University of Cape Town. Written informed 
consent was obtained from all mothers in their home language. All HIV 
testing was completed in conjunction with informed consent and pre-and 
post-test counselling. 
  
5.3.2 Blood collection and intracellular cytokine assay 
One mL blood was collected at 10, 20, and 50 weeks of age in heparinized 
syringes. Whole blood was processed within 2 hours of collection, as 
previously described (178). Briefly, 250µL whole blood was incubated for 12 
hours at 37°C with viable BCG (reconstituted from the vaccine vial, Danish 
strain, Staten Serum Institute, 1.2 x 106 CFU/mL) and the co-stimulatory 
antibodies anti-CD28 and anti-CD49d (BD Biosciences, 0.5µg/mL each). 
250µL blood incubated with SEB (Sigma, 10µg/mL), and 250µL incubated 
with the co-stimulatory antibodies alone (unstimulated) served as positive 
and negative controls, respectively. Brefeldin-A (Sigma, 10µg/mL) was added 
for the last 5 hours of incubation. Following incubation, red blood cells were 
lysed and white cells fixed with BD FACS Lysing Solution (BD Biosciences), 
and the cells cryopreserved. 
 
Cryopreserved cells were later thawed and washed in 1% bovine serum 
albumin (Sigma) in phosphate buffered saline (PBS, BioWhittaker), and 
permeabilised using Perm/Wash Solution (BD Biosciences). Cells were then 
stained with the following antibodies: anti-CD3 Pacific Blue (clone UCHT1), 
anti-CD4 PerCPCy5.5 (SK3), anti-CD45RA PECy7 (L48), anti-IFN-γ 
AlexaFluor 700 (B27), anti-IL-2-FITC (5344.111), anti-TNF-α-PE (MAb11; all 
from BD Biosciences), anti-CD8 Qdot605 (3B5, Invitrogen) and anti-CCR7 
APC (150503, R&D Systems). After washes, cells were acquired on a LSR II 
flow cytometer (BD Biosciences), for this experiment configured with 3 lasers 
and 10 detectors, using FACS Diva 6.1 software (the SOP used for this 
staining is given in details in chapter 2, appendix II). Compensation settings 
were set using anti-mouse kappa-beads (BD Biosciences), labelled with the 











used to compensate and to analyze the flow cytometric data. Boolean gating 
was applied to generate combinations of cytokine expressing CD4 and CD8 
T cell subsets (Figure 42B). 
 
5.3.3 Assay of intercurrent M.tb infection 
At each time point, whole blood was diluted 1:5 in RPMI-1640 tissue culture 
medium (Sigma), containing 1% L-glutamine (Sigma), and incubated with 
ESAT-6/CFP-10 fusion protein (provided by Tom Ottenhoff, Leiden University 
Medical Centre, 10µg/mL), phytohemagglutinin (PHA, Sigma, 5µg/mL) and 
SEB (1µg/mL; both positive controls), or no antigen (negative control), in 
triplicate, in 96-well plates (modified from Black et al.) (267). Plates were 
incubated at 37°C with 5% CO2 for 7 days, supernatants were harvested, 
triplicate wells pooled and stored at -80°C. Later, supernatants were thawed, 
and an IFN-γ sandwich ELISA was used to quantify IFN-γ in the supernatants 
derived from the 7-day whole blood assay, (BD Pharmingen). A positive IFN-
γ response was defined as 62pg/mL, after background subtraction (twice the 
assay detection limit of 31pg/mL). Infants with evidence of intercurrent M.tb 
infection/ exposure at 10, 20 or 50 weeks of age, were excluded from 
analysis. 
 
5.3.4 Data analysis  
For the intracellular cytokine assay, cytokine expression levels from 
unstimulated blood were subtracted from levels obtained after BCG or SEB 
stimulation. (The median level of expression of IFN-γ, IL-2 and TNF among 
CD4 T cells in unstimulated blood was 0.002%, 0.03% and 0.06%, 
respectively.) Differences in participant birth weights and gender were 
assessed using parametric tests. The Mann-Whitney U test was used to 
assess differences in frequencies of cytokine expressing CD4 and CD8 T 














5.4.1 Participant characteristics 
A total of 46 infants were enrolled into this study: 25 in the birth group and 21 
in the delayed vaccination group. Infants not present for phlebotomy at a 
certain time point, bled beyond the defined window period at week 10 visit, or 
positive for M.tb infection were excluded from analysis (Figure 41). Results 
from infants with M.tb infection were excluded from the time point at which 
this was diagnosed, and from subsequent time points. At baseline, no 
differences were observed in birth weights or gender between the birth and 
delayed vaccination groups (mean birth weight, (SD): 3306g (435.6) birth vs. 
3200g (371.9) delayed; p=0.390). Sixteen (64%) infants in the birth group 













Figure 41: Overview of eligibility, study flow and participants. Participants randomized 
to receive BCG at birth or at 10 weeks were followed up to 1 year of age. Exclusions were 
made either due to M.tb infections and/or absence of the participants at the specified range 













5.4.2 Gating strategy for the analysis of BCG-specific T cells 
To analyse BCG-specific T cells, we performed ICS as described in the 
methods section. We first excluded doublets by use of a singlet gate. We 
then selected for lymphocytes based on the size and granularity 
characteristics of the cells (SSA vs FSA). We subsequently gated on CD3 
expressing cells and further delineated T cells as CD4 or CD8 (Figure 42A). 
Intracellular expression of IL-2, IFN-γ and TNF-α were assessed in these T 
cell subsets. The cytokine expression profiles were assessed in the 
unstimulated, BCG and SEB conditions, and a representative example is 
shown (Figure 42B). Finally, a boolean gating strategy was applied to 













Figure 42: Gating strategy. Whole blood was left unstimulated or was incubated with BCG 
or SEB, and analysed as described in the Methods. (A) Doublet cells were excluded by 
gating on Forward Scatter–Area (FSC-A) against Forward Scatter-Height (FSC-H), followed 
by lymphocyte selection in a FSC-A against Side Scatter-Area (SSC-A) gate. Subsequently, 
cell surface antibody markers were used to select for T cells. T cells were selected by gating 
on CD3+ events, which were further differentiated into CD4 and CD8 T cells. (B) 
Representative dot plots of cytokine co-expression patterns in CD4 T cells from 
unstimulated, BCG and SEB-stimulated conditions. 
 
 
5.4.3 Detection of BCG-specific CD4 T cells using viable BCG as 
antigen 
Before comparing BCG-induced immunity between infants who received birth 
and delayed vaccination, we evaluated whether incubation of whole blood 











vaccination-specific response would be detectable. We compared CD4 T cell 
immunity, measured at 10 weeks of age with an intracellular cytokine 
detection assay, between participants who had received BCG at birth and 
those who had not yet received BCG (infants in the delayed group). Cytokine 
production by CD4 T cells was readily detectable in infants from the birth-
vaccinated arm, but was not detectable, or barely detectable in infants who 
had not received the vaccine at birth (Figure 43). The birth-vaccinated 
infants had high frequencies of BCG-specific polyfunctional CD4 T cells, i.e., 
CD4 T cells that express IFN-γ, TNF-α and IL-2 together, and of CD4 T cells 
expressing other combinations of Th1 cytokines. Polyfunctional BCG-specific 
CD4 T cells were absent in infants in the delayed vaccination group. All 
infants had a positive response to the positive control, SEB. We concluded 
that T cell responses measured by the short-term whole blood assay system 
when BCG is used as antigen, are antigen-specific and not due to non-













Figure 43: Comparison of CD4 T cell responses following incubation of whole blood 
from BCG-vaccinated and unvaccinated infant’s blood with BCG, at 10 weeks of age. 
When BCG is used as a re-stimulation antigen in the short-term whole blood assay, only 
CD4 T cells that have previous sensitization to the vaccine respond. The frequencies of 
cytokine-expressing CD4 T cells detected by a whole blood intracellular cytokine assay (see 
methods) are shown. The median is represented by the horizontal line, the interquartile 
range by the box, and the range by the whiskers. The Mann-Whitney U test was used to 
calculate p values for differences between the 2 groups. 
 
 
5.4.4 Delayed vaccination resulted in moderately higher frequencies of 
BCG-specific CD4 T cells 10 weeks post-vaccination 
To assess differences in CD4 and CD8 T cell responses when the vaccine 
was given at birth or at 10 weeks at age, we measured the Th1 cytokine 
expression pattern induced by BCG, 10 weeks after vaccination, i.e., at 10 
weeks of age in the birth group and at 20 weeks of age in the delayed group. 
In both groups, high frequencies of polyfunctional CD4 T cells, or cells 
expressing other combinations of the Th1 cytokines, were observed (Figure 
44A). The IFN-γ+ and IFN-γ+IL-2+ BCG-specific CD4 T cell subset frequencies 
were significantly higher in the delayed-vaccination group, compared with the 
birth-vaccination group (Figure 44A). As the frequencies of BCG-specific 











BCG-specific CD8 T cell responses were evaluated: there was no difference 
between the two groups (Figure 44 B). We concluded that delaying BCG 
vaccination by 10 weeks might result in an increased frequency of BCG-
specific CD4 T cells, 10 weeks after vaccination. 
 
 
Figure 44: Comparison of BCG-specific CD4 T cell responses in the 2 groups of 
infants 10 weeks post-vaccination. (A) Frequencies of BCG-specific cytokine expressing 
CD4 T cells are shown, as detected by the whole blood intracellular cytokine assay. (B) 
Frequencies of all expressing CD8 T cells, evaluated together, after incubation of whole 
blood with BCG. The median is represented by the horizontal line, the interquartile range by 
the box, and the range by the whiskers. The Mann-Whitney U test was used to calculate p 
values for differences between the 2 groups. 
 
 
5.4.5 SEB-induced CD4 T cell responses at 10 weeks post-vaccination 
does not differ with the birth or delayed BCG administration  
A positive control in this assay was used to evaluate if the assay was 
successful. SEB is a superantigen that stimulates T cells via selective 
crosslinking of the T cell receptor/ CD3 complex with MHC class II molecules 
irrespective of the cell’s previous antigen-specific exposure (268). Thus, the 
SEB-induced response should be comparable irrespective of the BCG 
vaccination schedule, in this assay. To confirm this, we therefore evaluated 











specific responses that showed moderately higher frequencies in the delayed 
group at this time point, SEB responses were comparable in the two groups, 
except the birth-vaccinated group had a higher single TNF-α expressing 
subset (p=0.008) than the delayed group (Figure 45). These results further 
reinforce the validity of the BCG-specific responses, and the differences 
between the 2 vaccination groups. 
 
 
Figure 45: Comparison of SEB-induced CD4 T cell responses in the 2 groups of 
infants 10 weeks post-vaccination. Frequencies of SEB-induced cytokine expressing CD4 
T cells are shown, as detected by the whole blood intracellular cytokine assay after 
incubation of whole blood with SEB. The median is represented by the horizontal line, the 
interquartile range by the box, and the range by the whiskers. The Mann-Whitney U test was 
used to calculate p values of differences between the 2 groups. 
 
 
5.4.6 Delayed vaccination increased frequencies of polyfunctional BCG-
specific CD4 T cells at one year of age  
We also compared the BCG-specific memory response at 50 weeks of age. 
We observed significantly higher frequencies of BCG-specific polyfunctional 











with the birth vaccination group (Figure 46). Frequencies of specific T cell 
subsets co-expressing TNF-α and IL-2, TNF-α and IFN-γ, or TNF-α alone, 
were also higher in the delayed vaccination group. At this age, total BCG-
specific CD8 T cell responses were too low for reliable data analysis. 
 
 
Figure 46: BCG-specific CD4 T cell responses in the 2 groups of infants at 1 year of 
age. Frequencies of cytokine-expressing CD4 T cells detected by a whole blood intracellular 
cytokine assay are shown. The median is represented by the horizontal line, the interquartile 
range by the box, and the range by the whiskers. The Mann-Whitney U test was used to 
calculate p values of differences between the 2 groups. 
 
 
5.4.7 SEB-induced CD4 T cell responses at one year of age was 
comparable in the birth and delayed vaccination groups  
When we compared SEB responses between the 2 groups at one year of 
age, no differences were observed for any of the subsets (Figure 47). We 
concluded that delaying BCG vaccination from birth to 10 weeks of age 
results in a quantitatively increased and qualitatively more optimal BCG-












Figure 47: Comparison of SEB-induced CD4 T cell responses in the 2 groups of 
infants, at 1 year of age. Frequencies of cytokine-expressing CD4 T cells detected by a 
whole blood intracellular cytokine assay are shown for the positive control, SEB, used in this 
study. The median is represented by the horizontal line, the interquartile range by the box, 
and the range by the whiskers. The Mann-Whitney U test was used to calculate p values of 
differences between the 2 groups. 
 
 
5.4.8 The kinetics of BCG-specific CD4 T cell response was similar in 
the birth and delayed vaccination groups 
To assess whether the BCG-specific CD4 T cell responses follow a similar 
kinetic pattern if vaccination is given at birth or at 10 weeks, the total 
cytokine- and cytokine expression subsets of BCG-specific CD4 T cells were 
measured longitudinally, at 10, 20 and 50 weeks of age. Total responses are 
denoted by BCG-specific CD4 T cells that express IFN-γ, TNF-α, or IL-2, 
alone or in combination. Proportions are denoted by the frequencies of 
polyfunctional (3+ cytokines), bifunctional (2+ cytokines), or monofunctional 
(1+ cytokines) BCG-specific subsets of all the cytokine expressing cells. In 
the delayed vaccination group, all of the CD4 subsets peaked 10 weeks post-
vaccination, and diminished gradually over the first year of life (Figure 48A 











for the IFN-γ-TNF-α+IL-2+ and IFN-γ-TNF-α-IL-2+ BCG-specific CD4 subsets 
that peaked 20 weeks post-vaccination, and diminished gradually over the 
first year of life (Figure 48D and G). The two subsets that peaked at 20 
weeks in the birth group expressed IL-2, a cytokine associated with the 
maintenance of memory T cells. The proportion of specific polyfuctional T 
cells in the delayed group increased slightly from 20 to 50 weeks, whilst this 
proportion decreased marginally in the birth vaccinated group (Figure 48I, 















Figure 48: Kinetics of BCG-specific CD4 T cells responses in the delayed and birth 
vaccination groups over one year. Median frequencies of the profiles of BCG-specific CD4 
T cells detected by a short-term whole blood intracellular cytokine assay at 10, 20 and 50 
weeks of age. (A) polyfunctional IFN-γ+TNF-α+IL-2+, bifunctionals (B) IFN-γ+TNF-α+IL-2-, (C) 
IFN-γ+TNF-α-IL-2+, (D) IFN-γ-TNF-α+IL-2+, monofunctionals (E) IFN-γ+TNF-α-IL-2-, (F) IFN-γ-
TNF-α+IL-2-, (G) IFN-γ-TNF-α-IL-2+, (H) Total cytokines (I) proportions of polyfunctionals (3+), 












5.4.9 Comparable BCG-specific CD4 T cell memory phenotype between 
birth and delayed vaccination groups 
To assess whether delaying BCG vaccination results in an altered vaccine 
specific CD4 T cell memory phenotype, we characterized cytokine 
expressing BCG-specific T cells. The memory phenotype of specific CD4 T 
cells, as defined by surface expression of CD45RA and CCR7, has in animal 
models been shown to determine vaccination outcome (269). In both the 
birth-vaccination and delayed-vaccination groups, effector memory 
(CD45RA-CCR7-, TEM) T cells predominated at all time points evaluated 
(Figure 49 for data at 1 year of age). At one year of age, there was no 
significant difference for TEM or central memory (TCM, CD45RA-CCR7+) in the 












Figure 49: Comparison of the memory phenotype of BCG-specific CD4 T cells 
between the 2 groups of infants, at 1 year of age. BCG-specific CD4 T cells were 
identified by cytokine expression using the whole blood intracellular cytokine assay. (A) Box 
and whisker plots depicting the memory phenotype of all BCG-specific CD4 T cells analysed 
together. (B) Representative dot plots of the memory phenotype of BCG-specific CD4 T cells 
(dots), superimposed on the memory phenotype of all CD4 T cells (contour plots). The 
median is represented by the horizontal line, the interquartile range by the box, and the 
range by the whiskers. The Mann-Whitney U test was used to calculate p values of 
















Our study showed that delaying BCG vaccination from birth to 10 weeks of 
age results in induction of higher frequencies of detectable specific CD4 T 
cells. In addition, the specific CD4 T cells were more likely to be 
polyfunctional in the delayed vaccine group, indicating that the “quality” of the 
BCG-induced response was enhanced.   
 
Our results differ from those reported in two earlier studies, which did not 
show a difference in T cell immunity when BCG vaccination was delayed 
(136, 258). Importantly, both those studies used IFN-γ measurement alone 
as outcome. We showed that the most striking differences in induced 
immunity were at one year of age, highlighting the importance of a 
longitudinal design of such studies. Data on the kinetics of the BCG-induced 
immune response in infant cohorts is limited, especially in high TB endemic 
settings. Our laboratory has ongoing detailed studies aimed to evaluate the 
kinetics of the BCG-specific T cell response over the first year of life within 
shorter time intervals. 
 
The immune correlates of vaccination-induced protection against TB are not 
known. In a 2-year follow up study, we have shown in chapter four that the T 
cell cytokine expression patterns may not correlate with risk of childhood TB 
development. However, the frequencies of specific cells, patterns of cytokine 
production and memory phenotype remain the most widely evaluated 
outcomes in preclinical and clinical studies assessing immunogenicity of 
novel TB vaccines. Most vaccinologists would regard a quantitatively greater 
antigen-specific response as more optimal, following novel TB vaccination in 
clinical trials. This opinion has been substantiated by multiple animal studies, 
which have demonstrated that greater frequencies of specific T cells result in 
improved protection against TB (240-242). In contrast, other studies have 
shown that the frequency of antigen-specific T cells induced by a TB vaccine 
may not necessarily correlate with outcome after virulent M.tb challenge 
(243, 270-272). Study design variables, such as the time point evaluated and 











In addition, many of these studies evaluated specific T cells responses by 
IFN-γ production only. Protection against TB without an optimal IFN-γ 
response is not possible. However, it is postulated that measuring other Th1 
cytokines in addition to IFN-γ would allow a better assessment of the “quality” 
of the T cell response. For example, presence of polyfunctional T cells, co-
expressing IFN-γ, TNF-α and IL-2, has emerged as a useful readout of 
“quality” immune responses (273, 274). In animal models of vaccination 
against Leishmania major (237), and against TB (234), strategies that induce 
the highest frequency of polyfunctional antigen-specific CD4 T cells are 
associated with the best protection against subsequent challenge with the 
pathogen. Further, in HIV-1 infected individuals, slow disease progression is 
strongly associated with higher frequencies of polyfunctional HIV-specific T 
cells (275). 
 
Classically, CD45RA and CCR7 have been used to delineate T cells into 4 
memory subsets, namely naïve cells (CD45RA+CCR7+, TNaive), central 
memory cells (CD45RA-CCR7+, TCM), effector memory cells (CD45RA-CCR7-
,TEM), and effector memory cells that have re-expressed CD45RA 
(CD45RA+CCR7-, TEMRA) (276, 277). Long-lived TCM expand in lymph nodes, 
and differentiate into effector cells (276). In contrast, TEM or the more 
terminally differentiated TEMRA populations can immediately home to a 
disease site for effector functions, but their proliferative capacity and 
longevity are limited (276). From a hypothetical point of view, induction of 
longer-lived TCM should be a vaccination goal – this view has been 
substantiated in animal models of macaque infection with simian 
immunodeficiency virus (SIV) (269). In contrast, induction of TEM or TEMRA 
may not be as optimal, as these short-lived populations cannot expand, and 
are more prone to exhaustion (278). Interestingly, in most studies of human 
mycobacteria-specific T cells, TEM populations predominate and TCM are 
relatively infrequent (130, 212, 230, 279). Our findings corroborate this; 
however there were no significant differences in these T cell subpopulations 












Many variables are thought to affect BCG-induced immunity, as described in 
the introduction. For example, Lalor et al. reported that seasonal changes 
affected the IFN-γ response in BCG vaccinated infants, when measured by 
PPD stimulation of whole blood for 6 days (280). In our study, at 50 weeks of 
age when the most significant differences in BCG-specific immunity were 
observed, there was no significant difference in the distribution of birth 
season between the delayed-and-birth vaccination groups. Further, it is 
possible that variable exposure to environmental NTM could have 
confounded our results, although we regard this as unlikely, as all infants 
were enrolled from the same geographic area. We cannot exclude that other 
variables could have impacted on the results. At one year, the shorter period 
post vaccination in the delayed than birth vaccinated groups, may have 
confounded our results. However, we regarded this time point (one year) as 
optimal for comparison of established, long-lived (plateau-phase) memory 
immunity, long after the effector phase. 
 
Vries et al. reported that absolute counts of global T and B lymphocytes in 
healthy infants increased at one and six weeks after birth respectively (220). 
The same studies reported that over the first year of life, frequencies of 
memory CD4 and CD8 T cells, defined by the expression of CD45RO 
remained stable from six weeks of age to one year, but lower than 
frequencies of the same cell subsets in adults (220). So why did the immune 
response appear enhanced following delayed-BCG vaccination? The 
newborn’s immune response is often regarded as “immature”, when 
compared with that of adults (135). “Immature” may be a misnomer, as the 
response may be very appropriate for a baby emerging into a world of 
continuous antigenic challenge, and where excessive immunity to these 
stimuli may be detrimental. However, this may result in suboptimal responses 
to certain vaccines, such as BCG. We propose that the different nature of 
immunity induced by BCG at 10 weeks of age, compared with birth, could be 
ascribed to early “maturational” changes in infant immunity. Very limited data 
on “maturation” of the infant immune response over the first few months of 
life exists, but factors that may have contributed include inefficient antigen 











critical cytokine for inducing the Th1 responses characteristic of successful 
mycobacterial immunity. In addition, animal and human evidence suggests 
that the newborn’s immune system is skewed towards a Th2 response (281-
283), which may suppress induction of Th1 immunity. 
 
Unlike many infant vaccines that confer increased protection upon boosting, 
a second BCG vaccination has been shown not to enhance protection (284). 
New TB vaccination strategies focus on boosting immunity induced by BCG 
through use of heterologous vaccines. It is therefore critical that we use the 
prime vaccine most optimally. Our results suggest that the age at which BCG 
is administered may be a critical variable. The next step would be to confirm 
these findings in another cohort, prior to larger studies to assess whether 
delayed vaccination leads to increased protection against TB disease. 
Makerere University, in collaboration with our laboratory, has enrolled birth-
and-delayed BCG vaccination cohorts in Uganda, and studies are ongoing to 
compare the BCG-induced immunity from these cohorts, using more detailed 
assays. Should this study show similar results of enhanced immunity 
following delayed BCG vaccination, comprehensive assessment of the 
implications of delaying BCG vaccination to 8-14 weeks of age, when other 
childhood vaccines are given routinely, would be warranted. 
 
5.6 Contributions 
B.M.N. Kagina designed the experiments, conducted the laboratory and data 
analysis, and wrote this chapter under supervision of Prof. W.A. Hanekom, 
Dr. B. Abel, and other members of SATVI laboratory. A.C. Hesseling and 
other members of Stellenbosch University did study design, sample 











Chapter 6: General Conclusions 
We showed that long-term cryopreservation of fixed white blood cells from 
whole blood incubated with mycobacterial antigens immediately after 
collection does not compromise the detection of specific immunity with ICS. 
We also showed that mycobacteria-specific immunity, measured 10 weeks 
after newborn vaccination with BCG with this whole blood ICS assay, does 
not correlate with ultimate risk of developing childhood TB. Finally, we 
reported that delaying BCG vaccination schedule from birth to 10-weeks of 
age resulted in enhanced BCG-induced immunity. These results are highly 
significant to the field of TB vaccinology for several reasons.  
 
First, all our results were generated utilizing a short-term whole blood ICS 
assay, which is a commonly used method in the measurement of 
immunogenicity elicited by novel TB vaccines. All our blood samples were 
stimulated immediately after collection, and then processed followed by 
cryopreservation. This is similar to what is routinely done in TB vaccine 
clinical trials. Our results showed that stimulated fixed white blood cells 
retrieved after long-term cryopreservation are reliable for retrospectively 
addressing immunological questions. It is possible that novel TB vaccine 
candidates will demon trate efficacy prior to identification of immune 
correlates of protection against TB. In such a scenario, retrospective analysis 
of samples collected and cryopreserved during the clinical trial period, would 
be invaluable. 
 
There may also be limitations to the approach of immediate incubation and 
cryopreservation of fixed cells. This assay system does not allow flexibility in 
testing new antigens later. Future studies are important to investigate the 
feasibility of cryopreserving unstimulated whole blood (in addition to the 
current standard of PBMC cryopreservation), which would allow for the 
flexibility to introduce re-stimulation antigens post thaw. We propose that 
cryopreservation is a necessary aspect of vaccine development process that 
human research ethicists, vaccinologists and immunologists need to 











Secondly, we report that the immunological outcomes routinely evaluated in 
novel TB vaccine clinical trials, including BCG-specific polyfunctional CD4 T 
cells, may not correlate with risk of childhood TB development. Additional 
immunological outcomes should thus be considered for novel vaccine trials. 
Although specific polyfunctional T cells did not associate with the risk of 
developing TB in infants, these cells may be an essential component of TB 
immunity. In a clinical setting, unpublished data from our laboratory show that 
mycobacteria-specific polyfunctional T cells increase during TB treatment, 
suggesting emergence during recovery of the host response (Day et al., 
unpublished data). Conversely, Sutherland et al. has reported presence of 
higher frequency of mycobacteria-specific polyfunctional T cells in patients 
with TB disease, compared with persons with latent infection (285). 
Therefore, the association between risk of developing TB disease and 
presence of mycobacteria-specific polyfunctional T cells remains unclear. We 
hypothesize that the risk of developing or not developing TB may involve a 
balance between host inflammation and immune regulation. Decoding the 
critical components of an optimal balance between these two arms of the 
immune response within a host may provide elucidate immune correlates of 
risk of TB disease.  Until we have validated correlates of protection against 
TB disease, our whole blood ICS outcome should best be termed “vaccine 
take” in these trials. Correlates of protection may be defined only in a 
randomized controlled trial of an effective vaccine (99). In the interim, studies 
of correlates of risk of TB disease, such as the study reported here, may 
require complementary and novel approaches for success. We propose that 
we should complement hypothesis-driven approaches, such as the current 
study, which focused on T cell knowledge, with data-driven approaches, 
which are not restricted by our limited knowledge. Examples of data driven 
approaches include whole genome expression screens, proteomic analysis 
and metabolomics (103). The results obtained from these approaches should 
generate new hypotheses, including novel T cell approaches.  
 
Finally, we report that BCG immunogenicity is enhanced when the vaccine is 
delayed by 10 weeks after birth. Most novel TB vaccine strategies involve 











under development, most are far from clinical application. In the interim, we 
propose that studies should be conducted to determine the most optimal 
manner to prime immunity with the current BCG. We are currently testing, in 
another cohort from Uganda, whether our result of “better” priming when the 
vaccination is delayed, can be confirmed. A positive finding might have to 
lead to studies to determine the exact age at which BCG should be given, 
and these results might have far reaching implications on vaccination policy. 
Additionally, these findings may be encouraging to the public health sector in 
developing countries where home births are common, and BCG vaccination 
at birth is not feasible, for practical and logistical reasons. For example, prior 
to routine introduction of antiretrovirals in South Africa early after diagnosis of 
HIV infection in infants, an estimated 110-417 cases of BCGosis were 
reported per 100,000 BCG vaccinations (156). These findings have resulted 
in a revised recommendation by the WHO Global Advisory Committee on 
Vaccine Safety to not routinely vaccinate infants born to HIV-infected 
mothers at birth (286). This policy is difficult to implement in developing 
settings; therefore, babies born to HIV-infected mothers will benefit from 
delayed vaccination – infants who are HIV-infected may then be excluded. 
 
Immunological outcomes reported in this thesis indicate that BCG-induced 
immune responses are highly variable between individuals. Our group is 
hypothesizing that this variability may indicate differential host responses to 
BCG. This means that examining all infants together, without taking into 
account heterogeneity in responses, may mask correlates of risk that may be 
present in some groups of infants. Other investigators in our group are 
currently addressing these hypotheses, primarily through studies of gene 
expression. Findings from these analyses will contribute significantly to the 
field of TB vaccinology. 
 
6.1 Contributions 
B.M.N. Kagina wrote this chapter under supervision of Prof. W.A. Hanekom 
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